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    INTRODUCTION 
 
   Kalleral noi (Liver disease) is invariably applied to many disease and disorder, 
which cause the liver to function improperly and may lead even to stop functioning. 
Abnormal  pain, yellowing of skin or eye (jaundice) or abnormal result of liver function 
test are the suggestion features of Kalleral noi (Liver disease)1. 
 It can caused by many different injuries to liver such as infection with HCV, HBV 
and other condition like obesity, chronic excessive alcohol consumption, autoimmune 
disease etc..                    
 Liver disease often lead to lifelong problem and serious consequences. Worldwide 
liver disease affect hundreds of millions of patients. The increasing incidence of liver 
disease and liver failure throughout the world have also been reported in  India 
nowadays2. 
 At least 1 in 5 Indians is affected with some manifestation of liver diseases. The 
incidence of liver disease is more in males as compared to females.3 Statistic  reports 
reveal that nearly 2 lakhs people in India die of liver disease. 
 Complementary and alternative medicine use is common among patient visiting 
liver disease clinics in US as in general population (39% Vs 42%) many patients are 
using to treat their liver disease.4 
 Due to deforestation, urbanisation plants availability are reduced and so we need 
other than plant product to treat liver disease. 
 The traditional herbomineral receipe is fast acting powerful  hepatic stimulant. It 
increases the function of capacity of  the liver and promotes regeneration and varying 
positive findings have been reported in several manuscripts. It give support to remarkable 
improvement in appetite.5 
 Kalleral noi (Liver disease) is due to derangement of Pitham. According to Siddha 
the bitter taste tends to neutralise the Pitham derangement. Palagarai  is a marine drug, 
which has bitter taste.6  
 In the present scenario, scientific validation and clinical evaluation in tradition 
medicine system are needed to bridge between tradition medicine system are needed to 
bridge between tradition and temporary science to reassure the facts said the Ancient.7 
 Hence the author selected Palagarai Parpam which is mentioned in "Kannusami 
Parambarai Vaithiyam" for Kalleral noi.8  
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AIM: 
 To evaluate the safety and efficacy of “Palagarai Parpam" for Hepatoprotective    
activity in the management of  Kalleral noi (Liver disease). 
 
OBJECTIVE: 
Primary objective: 
To evaluate the Hepatoprotective activity of “Palagarai Parpam” for Kalleral noi  
(Liver disease) in preclinical studies. 
 
Secondary objective: 
 Biochemical analysis. 
 To evaluate the efficacy of  “Palagarai Parpam” for Hepatoprotective activity in 
the management of  Kalleral noi (Liver disease). 
 Atomic Absorption Spectrophotometer. 
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MATERIALS AND METHODS 
STANDARD OPERATIVE PROCEDURE: 
 
COLLECTION AND AUTHENTICATION OF RAW DRUGS: 
The raw drug was procured from Ramasamy chetty shop Paris Chennai and 
authenticated by competent authority of  department of Gunapadam, National Institute of 
Siddha. 
PREPARATION OF THE MEDICINE: 
INGREDIENTS: 
  Purified Palagarai (Cyperae monetae) 
 Lemon juice 
PURIFICATION METHODS:9   
 Purification of  Palagarai: 
  Palagarai soaked in lemon juice and washed  well in water. 
 
 METHOD OF MEDICINE PREPARATION:8 
 Palagarai soaked in lemon juice for  one  night and then covered with mud cap 
with clay pasted cloth. Then it was calcinated with 30 – 40 cow dung cake. Uncover the 
mud cap and grind the outcome as fine powder. The powder was stored in a clean ,dry air 
tight glass bottle. 
 
LABELLING: 
Name of the preparation : Palagarai Parpam 
 Quantity of the drug  : 2gm 
 Dose    :130 mg, twice a day 
 Adjuvant or Vehicle  : Ghee 
 Indication      : Palagarai Parpam 
 Date of manufacturing :1/4/12 
 Date of expiry   :100 years from the date of manufacture9 
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Palagarai ( Cypraea  moneta ) 
 
 
 
 
 
 
 
 
Palagarai Parpam 
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REVIEW OF THE LITERATURE 
    GUNAPADAM ASPECT   
  
gyfiw 10 
ntWbga® :  fto, nrh», tuho 
 “k©Âa fto nrh» tuhona gyfiw¥ng®” 
Rit : if¥ò   
brŒif :  jhJbt¥gf‰¿, nfhiHaf‰¿, bt¥gf‰¿ 
bghJFz« : 
 “kªjªjh f§»ufÂ khÉl¢ Ru§f©nzhŒ 
 bjhªj« gÇehk¢ Niyfa - Äªj 
 îyfiwia¡ fhnyhoit nahLeiu¤j 
 gyfiwia fhÂÅa« gh®” 
 
Fz« : 
 myr«, jhf«, »ufÂ, kfhÉl Ru§fŸ, ÉÊnehŒ, thj bjhªj«, 
gyÉj¡ F¤jš fa«, fgthj«, méuz«, fhkhiy, fšäuš, k©Ùuš, 
å¡f«, Rthrfhr«, fhr« KjÈa nehŒfŸ ÔU«. 
 
R¤â Kiw :9 
1. xU gy« gyfiw bgho¡F g¤Jgy« jku¤j« gH¢rhW fhiyÆš 
É£L khiy tiu btÆÈš it¤J vL¤J kWehŸ fhiyÆY« 
òâjhf nk‰go rh‰iw É£L btŒÆÈš it¡fî«.  ïJnghš 
gâidªJ eh£fŸ brŒbjL¡f R¤âahF«. 
2. gyfiwia vYÄ¢ir gH¢rh‰¿nyD« mÇá¡ fŠáÆnyD« 
Cwit¤bjL¡f R¤âahF«. 
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vYÄ¢ir10 
(Citrus acidica) 
 
Rit : òË¥ò, fh®¥ò, j‹ik :  bt¥g«,  ãÇî : fh®¥ò 
brŒif : FË®¢áí©lh¡» 
Fz« : 
 “jhf« FefnehŒ jhHh¢ áÈgjnehŒ 
 ntf§bfhŸ c‹khj« åWã¤j« - khf©nzhŒ 
 f‹dndhŒ thªâí«ngh§ f£Lth â¤bjhÊÈš 
 k‹bdYÄ¢ r§fÅia thœ¤J” 
 ïJ, ka¡f«, thªâ, thŒ¡Fk£lš, Ú®nt£if, bt¿, f©nzhŒ, 
fhJtÈ ïitfis¥ ngh¡F«; ef¢R‰W¡F« e‹ik jU«. 
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nrU« kUªJfŸ 
 
 ÀÄ¸¨È ÀüÀõ: 
 «Ç×            :1-1 1/2 ÌýÈ¢ 
 «ÛÀ¡Éõ     :±ÖÁ¢î¨º ÀÆîº¡Ú 
 ¾£Õõ §¿¡ö    : ®Ãø¸Ç¢ý Å£ì¸õ  
 ¬¾¡Ãõ         :À¾¡÷ò¾ Ì½Å¢Çì¸õ 
ÀÄ¸¨È ÀüÀõ: 
 «Ç×              :1-1 1/2 ÌýÈ¢ 
 «ÛÀ¡Éõ      :¦Åñ¦½ö/¦¿ö   
 ¾£Õõ §¿¡ö      : ÅÂ¢üÚ §¿¡ö, Á§¸¡¾Ãõ, ¯ôÒºõ, ¦ÀÕÅÂ¢Ú 
 ¬¾¡Ãõ           : «Û§À¡¸ ¨Åò¾¢Â ¿Å¿£¾õ 
 ÀÄ¸¨È ÀüÀõ: 
 «Ç×            :1-2 ÌýÈ¢ 
 «ÛÀ¡Éõ     : ¦Åñ¦½ö/¦¿ö /§¾ý  
 ¾£Õõ §¿¡ö     : À¢ò¾ºÁó¾Á¡É §¿¡ö 
        ¬¾¡Ãõ           :«Û§À¡¸ ¨Åò¾¢Â ¿Å¿£¾õ  
 ÀÄ¸¨È ÀüÀõ: 
 «Ç×               :2-4 ÌýÈ¢ 
 «ÛÀ¡Éõ        : ¦Åñ¦½ö/¦¿ö /§¾ý  
 ¾£Õõ §¿¡ö       : ÅÂ¢üÚ ÅÄ¢ 
        ¬¾¡Ãõ             :«Û§À¡¸ ¨Åò¾¢Â ¿Å¿£¾õ 
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ZOOLOGICAL ASPECT 
 
Cypraea  moneta11 
 Cypraea moneta (money cowry), is a species of a marine gastropod mollusk in the 
family Cypraeidae, . This cowry lives in intertidal rocky areas and shallow tide pools 
among sea weed, coral remains, and empty bivalve shells. It can be found on and under 
rocks in shallow water and on exposed reefs at low tide. It feeds on algae and marine 
vegetation growing on loose rocks and pieces of dead coral. 
 
ZOOLOGICAL  NAME:  Cypraea moneta   
 Classification12  
Kingdom   :  Animalia 
Phylum    :Mollusca 
Class        :Gastropoda 
Orderd             : Sorbeoconch 
Superfamily : Cypraeoidea 
Family  :Cypraeidea 
Genus  : Cypraea 
Species : Cypraea moneta   
 
VERNACULAR NAME:13 
  ENGLISH            : Cowry 
  SANSKRIT       : Varatika 
  HINDI                  : Cowries 
  TELUNGU          : Gavala 
  MALAYALAM : Kavadi 
 
 DESCRIPTION:   
 The shell is 30 to 45 mm long. It is white to straw-colored.1 Small, convoluted 
,glossy shell of variegated colours, oblong oval shape varying in size from a tamarind 
seed to an almond. The upper surface is smooth, shining and convex. Base is compressed 
with a cleft in the centre which is runs longitudinally. The margin of the cleft is serrated 
on one side and other side is depressed. 
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DISTRIBUTION: 
 This is a very common species which is found widely in Indo-Pacific tropical 
waters. It is present in numerous regions, including East and South Africa, Madagascar, 
the Red Sea and the Persian Gulf, eastern Polynesia, Galapagos, Clipperton and Cocos  
islands off Central America, southern Japan, Midway and Hawaii, and northern New 
South Wales and Lord Howe Island. 
VARITIES: 
  White, red, yellow.  Different colours of Cowry are dependent on the 
sexual hormone, genetic factors, pigmentation, disease, injury, diet, Presence or absence 
of aluminium and other compounds , the acidity of the soil and water15. 
 Ancient Hindu alchemists preferred shells which were  yellow colour, knotty and 
possessed of circular lines  on dorsal side13.  
 
PHYSICAL CONSTANTS: 
  Insoluble in water, soluble in hydrochloric acid with effervescence.  
 
CHEMICAL CONSTITUENTS:  
  Phosphate, flouride and carbonate of calcium, magnesium phosphate, 
mangenese and sodium chloride. 
 
PHARMACOLOGICAL ACTIVITIES:16  
 Anti- spasmodic activity, anti -microbial activity.  
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vYÄ¢ir 
BOTANICAL  NAME                : Citrus  acida17 
VERNACULAR NAME       : 
  ENGLISH            : Lime 
  SANSKRIT       : Jambira 
  HINDI                  : Nimbu limu 
  TELUNGU          : Nimma 
  MALAYALAM   : Cheru-naranga 
 
BOTANICAL DESCRIPTION : 
 Fruits usually small, globose or ovoid ;rind thick or thin; pulp pale, very acid.  
PARTS USED: 
  Fruit 
PHARMACOLOGICAL ACTIVITIES:18 
USES; 
  The fruit has a sour sharp taste ;appetiser, stomachic ,anthelmintic, cures 
abdominal complains, removes diseases due  to "thridosha", loss of appetite, constipation, 
fatigue, good in" kapha "and biliousness, abdominal pain, and foul breath; relieves 
vomiting; good for the eyes. 
 The fruit has a sour sharp taste; with flavours; stimulant: useful in weakness and 
trembling of the limbs hemicrania, throat troubles, brain disorder , relieves biliousness, 
vomiting, retching,  improves liver, heart. 
 
Supportive Journals: 
 The analysis of the Cowry bhaspam shows that the overall decarbonation of 
calcium carbonate in argonite form  and reformation of calcium carbonate  in the 
calcinate form. The transformation occur via formation of Calcium hydroxide and  
Calcium oxide as intermediate. Cowry bhaspam is highly crystalline Calcium carbonate 
ih the calcite form with presence of trace element like  Mg, Al, K, Fe. It Pharmacological 
activity shows that 10% of all Cowries had been investigated in detail for bioactive 
agent.19 
 Cowry Bhaspam contain Phosphate, Fluoride and Carbonate of Calcium , 
Magnesium Phosphate and  Manganese.20 
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    PHYSICAL PROPERTIES  
 
Materials and Methods 
The Physical properties of Palagarai  Parpam were analysed in the following 
procedure at Sri Ramachandra University. 
pH at 10% of aqueous solution: 
Five grams of Palagarai  Parpam was weighed accurately and placed in clear 100 
ml beaker. Then 50 ml of distilled water was added to it and dissolved well. After 30 
minutes it was then applied in to pH meter at standard buffer solution of 4.0,7.0,9.2. (Trail 
Drug 1Table -2). 
Ash Values: 
 The Ash values  measures-inorganic constituents present in the raw drug.  A high 
ash content explains its unsuitable nature to be used as a drug (Trail Drug1 Table -2). 
Total Ash 
 A little of extract was taken in a silica crucible previously ignited, cooled and 
weighed. It was incinerated by gradually increasing the heat not exceeding dull red heat 
(450°C) until free from carbon, cooled and weighed. The percentage of ash 
was calculated with reference to air- dried drug. The procedure was repeated to get the 
constant weight.  
(TRAIL Drug 1 Table -2) 
 
Water soluble ash 
 The total ash was boiled with 25 ml water and filtered through ash less filter paper 
(Whatmann 4.1). It was followed by washing with hot  water .The  filter paper  was dried  
and ignited in the silica crucible, cooled and the water insoluble ash was weighed. The 
water-soluble ash can be calculated by subtracting the water insoluble ash from the total 
ash.  
Acid insoluble ash 
 The total ash obtained was boiled for 5 minutes with 25 ml of (10% w/v) dilute 
hydrochloric acid and filtering through ash less filter paper ( Whatmann 4.1).  The filter 
paper was ignited in the silica crucible, cooled and insoluble ash was weighed.( Trail Drug 
1 Table -2) 
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BIO -CHEMICAL ANALYSIS OF PALAGARAI  PARPAM 
The biochemical analysis of the Palagarai Parpam was carried out in the 
Biochemistry lab, NIS 
. 
S.No 
EXPERIMENT OBSERVATION INFERENCE 
1.         Appearance of sample Light white in 
colour 
 
2. Solubility: 
a. A little(500mg) of the sample 
was shaken well with distilled water. 
b. A little(500mg) of the sample 
was shaken well with con. HCl/Con. 
H2So4 
Sparingly soluble 
 
 
Absence of Silicate 
3. Action of Heat: 
   A small amount(500mg) of the 
sample was taken in a dry test tube and 
heated gartly at first and then strong. 
 
 white fumes 
evolved  
 
 
Presence of Carbonate 
 
4. Flame Test: 
  A small amount(500mg) of the sample 
was made into a paste with con. HCl in 
a watch glass and introduced into non-
luminous part of the Bunsen flame. 
 No Bluish green 
flame appeared. 
Absence of Copper 
 
 
5. 
Ash Test: 
   A filter paper was soaked into a 
mixture of sample and dil. cobalt 
nitrate solution and introduced into the 
Bunsen flame and ignited. 
Yellow colour 
flame appeared. 
Presence of sodium 
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Preparation of Extract: 
5gm of Palagarai Parpam was weighed accurately and placed in a 250ml clean 
beaker and added with 50ml of distilled water. Then it was boiled well for about 10 
minutes. Then it was cooled and filtered in a 100ml volumetric flask and made up to 
100ml with distilled water. 
 
S.No EXPERIMENT OBSERVATION INFERENCE 
 I.Test For Acid Radicals   
1.  Test For Sulphate: 
a. 2ml of the above prepared extract 
was taken in a test tube to this added 2ml 
of 4% dil ammonium oxalate solution 
b. 2ml of the above prepared extracts 
was added with 2ml of dil-HCl was added 
until the effervescence ceases off. Then 
2ml of dil.Barium chloride solution was 
added. 
          Cloudy 
appearance present 
 
 
   Absence  
of Sulphate 
 
 
 
2. Test For Chloride: 
  2ml of the above prepared extract was 
added with dil. HCl till the effervescence 
ceases. Then 2ml of dil.silver nitrate 
solution was added. 
 Cloudy 
appearance 
presence. 
  Presence  
of Chloride 
3. Test For Phosphate: 
  2ml of the extract was treated with 2ml 
of dil.ammonium molybdate solution and 
2ml of con.HNo3. 
         No yellow 
appearance present 
   Absence  
of Phosphate 
4 
.  
Test For Carbonate: 
    2ml of the extract was treated with 2ml 
dil. Magnesium sulphate solution 
Cloudy appearance 
presence. 
  Presence.  
of carbonate 
5. Test For Nitrate: 
  1gm of the substance was heated with 
copper turning and concentrated H2So4 
and viewed the test tube vertically down. 
 
No Brown gas 
evolved. 
 
   Absence  
of Nitrate 
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6. Test For Sulphide: 
  1gm of the substance was treated with 
2ml of con. HCL 
No Rotten Egg 
Smelling gas. 
   Absence  
of Sulphide 
7. Test For Fluoride & Oxalate: 
  2ml of extract was added with 2ml of dil. 
Acetic acid and 2ml dil.calcium chloride 
solution and heated. 
No Cloudy 
appearance 
      Absence  
of fluoride and 
oxalate 
8. Test For Nitrite: 
  3drops of the extract was placed on a 
filter paper, on that-2 drops of dil.acetic 
acid and 2 drops of dil.Benzidine solution 
was placed. 
No Characteristic 
changes 
   Absence  
of Nitrite 
9. Test For Borate: 
  2 Pinches(50mg) of the substance was 
made into paste by using dil.sulphuric 
acid and alcohol (95%) and introduced 
into the blue flame. 
No Bluish green 
colour flame. 
   Absence  
of borate 
 II. Test For Basic Radicals   
1. Test For Lead: 
        2ml of the extract was added with 
2ml of dil.potassium iodine solution. 
No yellow 
Precipitate 
obtained. 
Absence of Lead 
2. Test For Copper: 
One pinch(50mg) of substance was made 
into paste with con. HClin a watch glass 
and introduced into the non-luminuous 
part of the flame. 
No Blue colour 
flame. 
No Blue colour 
precipitate formed. 
 
  Absence  
of copper 
 
 
3. Test For Aluminium: 
  To the 2ml of extract, dil.sodium 
hydroxide was added in 5 drops to excess. 
No Yellow colour 
appeared. 
   Absence   
of aluminium 
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4. 
 
Test For Iron: 
a. To the 2ml of extract,2ml of 
dil.ammonium solution was added. 
b. To the 2ml of extract 2ml  
thiocyanate solution and 2ml  of con 
HNo3 was added 
blood red colour 
appeared. 
 
 
 
Presence of Iron 
 
 
5. Test For Zinc:  
      To 2ml of the extract, dil.sodium 
hydroxide solution was added in 5 drops 
to excess and dil.ammonium chloride was 
added.  
 
No White 
precipitate was  
formed 
 
Absence of Zinc 
6. Test For Calcium:  
      2ml of the extract was added with 2ml 
of 4% dil.ammonium oxalate solution  
Cloudy appearance 
and white 
precipitate was 
obtained 
 
   Presence.  
of calcium 
7. Test For Magnesium:  
         To 2ml of extract dil.sodium 
hydroxide solution was added in drops to 
excess. 
 
            White 
precipitate was  
obtained 
 
   Presence  
of Magnesium 
8. Test For Ammonium: 
  To 2ml of extract 1 ml of Nessler's 
reagent and excess of dil.sodium 
hydroxide solution were added. 
 
  No Brown colour 
appeared 
 
     Absence  
 of ammonium 
9. Test For Potassium:  
   A pinch(25mg) of substance was 
treated of with 2ml of dil.sodium nitrite 
solution and then treated with 2ml of 
dil.cobalt nitrate in 30% dil.glacial 
acetic acid. 
 
No Yellowish 
precipitate was 
obtained. 
 
   Absence  
of Potassium 
10. Test For Sodium: 
    2 pinches(50mg) of the substance was 
made into paste by using HCl and 
introduced into the blue flame of 
Bunsen burner. 
 yellow colour 
flame appeared 
    Presence  
of sodium 
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11. Test For Mercury:  
2ml of the extract was treated with 2ml 
of dil.sodium hydroxide solution.  
No yellow 
precipitate was 
obtained 
 Absence  
of mercury 
12. Test For Arsenic:  
   2ml of the extract was treated with 
2ml of dil.sodium hydroxide solution. 
 
No brownwish red 
precipitate was 
obtained 
 
    Absence  
of arsenic 
 III. Miscellaneous   
1.
  
Test For Starch:  
  2ml of extract was treated with weak 
dil.iodine solution  
 
No  blue colour 
developed 
 
      Absence  
of starch 
2.
  
Test For Reducing Sugar:  
    5ml of Benedict's qualitative solution 
was taken in a test tube and allowed to 
boil for 2 minutes and added 8 to 10 
drops of the extract and again boil it for 
2 minutes. The colour changes are 
noted. 
 
Brick red colour 
not developed 
 
   Absence of  
reducing sugar 
3.
  
Test For The Alkaloids: 
a) 2ml of the extract was treated with  
2ml of dil.potassium iodide solution. 
b)  2ml of the extract was treated with  
2ml of dil.picric acid. 
c)  2ml of the extract was treated with 
2ml of dil.phosphotungstic acid. 
 
 
  
Yellow colour 
developed 
 
 
 
   Presence  
of Alkaloid 
4.
  
Test For Tannic Acid:  
  2ml of extract was treated with 2ml of 
dil.ferric chloride solution  
black precipitate 
was obtained 
    Absence  
of Tannic acid 
5.
  
Test For Unsaturated Compound: 
  To the 2ml of extract 2ml of 
dil.Potassium permanganate solution 
was added.  
 
Potassium 
permanganate was 
not decolourised 
 
     Absence  
of unsaturated 
compound  
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6.
  
Test For Amino Acid: 
    2 drops of the extract was placed on a 
filter paper and dried well. 20ml of  
Biurette reagent was added. 
 
violet colour 
developed 
 
   Presence  
of amino acids 
7. Test For Type Of Compound: 
    2ml of the extract was treated with 2 
ml of dil.ferric chloride solution.  No green colour 
developed 
 
 
No red colour 
developed 
 
 
 
No violet colour 
developed 
 
No blue colour 
developed 
Absence of oxy 
quinole 
pinephrine and 
pyro catechol 
Anti pyrine, 
Aliphatic amino 
acids and 
meconic  
acid are absent  
Apomorphine 
salicylate and 
Resorcinol are 
absent 
Morphine, 
Phenol cresol 
and hydro 
uinone are 
absent 
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Elemental Analysis using Atomic Absorption Spectrophotometer. 
(TRAIL DRUG 1 ,TABLE 3) 
 
The AAS of Palagarai Parpam was done at Sri Ramachanra University. In this 
method the sample, in the form of a homogeneous liquid, is introduced into a flame where 
thermal and chemical reactions create “free” atoms capable of absorbing, emitting or 
fluorescing at characteristic wavelengths.   
In Atomic Absorption Spectrophotometer (AAS) the majority of free atoms in the 
commonly used flames were in the ground state, but that the flames did not also have 
enough energy to excite these atoms.  A light source emitting a narrow spectral line of the 
characteristic energy is used to excite the free atoms formed in the flame.  The decrease in 
energy (absorption) is then measured. 
 
METHODOLOGY  
 
I. Microwave Digestion For Elemental Analysis 
Model Name: Multiwave3000 
Digestion Procedure: 
I. 200mg of the given sample is placed in a digestion vessel, acid is added and the 
mixture is heated for several minutes. After the digestion, the samples are diluted 
to a specific volume. If too much sample is used in wet digestion, the reaction 
mixture can become violent. The samples are placed in digestion vessels that fit 
directly into digestion racks. There are several different acids or mixtures of acids 
used for digestion, the most common of which is concentrated Hydrochloric acid. 
The samples are heated slowly at a high temperature. After digestion, the samples 
are diluted to the appropriate volume with deionized H2O.  
 
II. Elemental Analysis using Atomic Absorption Spectrophotometer 
The elemental analysis of digested samples have been determined by Atomic Absorption 
Spectrophotometer- Flame technique (AAS model 400 Perkin Elmer). Working standard 
solutions of Fe, Mg and Zn were prepared from stock standard solution of 1000 ppm from 
MERCK.  Using blank solution to zero the instrument performs the Calibration.  The 
standards are then analyzed and their absorbance recorded.  A graph of Absorbance Vs 
19 
 
Concentration is plotted.  Calibration of the instrument was repeated periodically during 
operation.  A blank reading was also taken and necessary correction was made during the 
calculation of concentration of various elements. 
The digested material was made upto 100 ml for analysis in an (AAS) atomic absorption 
spectrophotometer (Perkin Elmer). The results were calibrated using standard calibration 
curve. 
In AAS the Wave Length (nm), Flame type, Lamp source and Calibration range (ppm) of 
different elements have been used, are listed in table. 
 
   Instrumental conditions for elemental analysis 
 
Element Wavelength 
nm  
Light source Flame type 
Magnesium 285.2 HCL Air/Ac 
Iron 386.0 HCL Air/Ac 
Zinc 213.86 HCL Air/Ac 
    
Air/Ac: Air-Acetylene; HCL: Hallow cathode lamp 
 
Elemental Analysis using Flame photometer 
The analysis of Na, K and Ca of the digested samples have been determined by Flame photometer 
(Flame photometer 129- Systronics Make). see trail drug 1 table 3 
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TOXICITY STUDY 
ACUTE AND SUB ACUTE TOXICITY STUDY ON PALAGARAI    
PARPAM IN RODENTS. 
 
Animals  
 Mice of either sex weighing 25-30g and rats weighing 210-240g were obtained 
from the animal house of Vels University. The animals were used with the approval of the 
Institute animal ethics committee and obtained from Vels University, Chennai. They were 
fed with a balanced standard pellet diet and maintained under standard laboratory 
conditions, providing 24-280C temperature, standard light cycle (12 h light, 12 h dark) 
and water ad libitum.  
 Animals were kept in cages with raised floors of wide mesh to prevent 
coprophagy. Animal welfare guidelines were observed during the maintenance period and 
experimentation. The rats were randomly assigned to control and different treatment 
groups, six animals per group. The animals were acclimatized for one week under 
laboratory conditions.  
 
ACUTE TOXICITY STUDY-OECD 425 GUIDELINES 
 Acute oral toxicity test for the Palagarai  Parpam was carried out as per OECD 
Guidelines 425. As with other sequential test designs, care was taken to ensure that 
animals are available in the appropriate size and age range for the entire study. The test 
substance is administered in a single dose by gavage using a stomach tube or a suitable 
intubation cannula. The fasted body weight of each animal was determined and the dose 
was calculated according to the body weight. After the substance has been administered, 
food was withheld for a further 2 hours in mice. The animals were observed continuously 
for the first 4 h and then each hour for the next 24 h and at 6 hourly intervals for the 
following 48 h after administering of the test drug, to observe any death or changes in 
general behaviour and other physiological activities.  
 Single animals were dosed in sequence usually at 48 h intervals. However, the 
time interval between dosing is determined by the onset, duration, and severity of toxic 
signs. Treatment of an animal at the next dose was delayed until one is confident of 
survival of the previously dosed animal.  
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Observation of toxicity signs: General behaviour, respiratory pattern, cardiovascular 
signs, motor activities, reflexes, change in skin and fur, mortality and the body weight 
changes were monitored daily. The time of onset, intensity, and duration of these signs, if 
any, was recorded.  
Acute Toxicity study 
 Acute toxicity study was performed for Palagarai Parpam according to the acute 
toxic up and down method as per OECD guidelines 425, albino mice were used for acute 
toxicity study. The animals were kept fasting for overnight providing only water, after 
which the Palagarai Parpam was administered orally at the dose of 250, 500, 1000, 2000 
mg/kg and observed for 14 days. If mortality was observed in animals, then the dose 
administered was assigned as toxic dose. If the mortality was observed in animal, then the 
same dose was repeated again to confirm the toxic dose (TRIAL DRUG1   TABLE 5) 
 
SUB-ACUTE TOXICITY  
 In a 28-days sub acute toxicity study, twenty four either sex rats were divided into 
four groups of 6 rats each. Group I that served as normal control was administered with 
distilled water (p.o.) while groups II, III and IV were administered daily with the 
Palagarai  Parpam  (p.o.) for 28 days at a dose of 25mg, 50mg, 100mg/kg respectively. 
The animals were then observed daily for gross behavioural changes and any other signs 
of subacute toxicity.  
 The weight of each rat was recorded on day 0 and weekly throughout the course 
of the study, food and water consumption per rat was calculated. At the end of the 28 
days they were fasted overnight, each animal was anaesthetized with diethylether, 
following which they were then dissected and blood samples were obtained by cardiac 
puncture into heparinised tubes. The blood sample collected from each rat was 
centrifuged with 3000 X g at 4oC for 10 min to separate the serum and used for the 
biochemical assays.  
Hematological and blood biochemical analysis: 
 At the end of the study, all animals were kept fasted for 16-18 h and then 
anesthetized with anesthetic ether on the 28th day. Blood samples for hematological and 
blood chemical analyses were taken from retro orbital vein. Heparinized blood samples 
were taken for determining complete blood count (white blood cell count, differential 
white blood cell count, platelet count, red blood cell count, hematocrit, and hemoglobin) 
by semiautomated hematology analyzer.  
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 The serum from non-heparinized blood was carefully collected for blood 
chemistry and enzyme analysis like glucose, Creatinine, Total protein, Albumin, Total 
and Direct bilirubins, Serum glutamate-oxaloacetate transaminase (SGOT), Serum 
glutamate pyruvate transaminase (SGPT), and Alkaline phosphatase (ALP) were 
automatically determined using autoanalyzer. 
Necropsy:  
 All rats were sacrificed after the blood collection. The positions, shapes, sizes and 
colors of internal organs were evaluated. The Spleen, Testes, Pancreas, Lung, Liver, 
Brain, Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues were excised from all 
rats to visually detect gross lesions, and weighed to determine relative organs’ weights 
and preserved in 10% neutral formalin for histopathological assessment. The tissues were 
embedded in paraffin, and then sectioned, stained with haematoxylin and eosin and were 
examined microscopically. 
Statistical analysis ( Trial Drug 1 Table 6-13) 
 Values were represented as mean ± SEM. Data were analysed using one-way 
analysis of variance (ANOVA) and group means were compared using the Tukey-Kramer 
Multiple Comparison test using Instat-V3 software. P values < 0.05 were considered 
significant. 
 
RESULTS AND DISCUSSION 
 Animals were shown negligebale toxic Signs during the dosing period of 28 days. 
Results of body weight determination of animals of control and different dose groups 
exhibited comparable body weight gain throughout the dosing period of 28 days. During 
dosing period, the quantity of food consumed by animals from different dose groups was 
found to be normal with that of control animals. Ophthalmoscopic examination of 
animals in control and test product– treated groups did not reveal any major and 
remarkable abnormality.  
 Urine analysis data of control group and treated group of animals determined in 
week 4 and animals in week 6 did not reveal any remarkable abnormalities except few 
indications. Comparison of organ weights of treated animals with respective control 
animals on day 28 was found to be comparable except brain and kidneys. Gross 
pathological examination of animals in control as well as the treated groups revealed mild 
abnormalities like kidney damage. 
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 The results of haematological investigations conducted on day 28, revealed no 
significant changes in the values of different parameters investigated when compared 
with those of respective controls; However, the increase or decrease in the values 
obtained was within normal biological and laboratory limits. A slight increase in total 
RBC count values were obtained for animals in the dose group of 50 and 100 mg/kg and 
also decreased values of platelets (P>0.05) were observed for animals in dose groups 
administered 100mg/ kg body weight of Palagarai Parpam sacrificed on day 28.  
 
The results of Biochemical investigations conducted on days 28 revealed the 
significant changes in the values of ALP, Globulin, Urea, creatinine and uric acid at 50 
and 100 mg/kg dose level particularly when compared with those of respective controls. 
HDL, LDL, Triglyceride levels are elevated in animals of 25 - 100 mg/kg dose group 
(P<0.01). Glucose level decreased in animals of the entire drug treated group (P<0.01).  
 
CONCLUSION: 
 The results indicated the toxic effect at 500mg/kg of Palagarai Parpam treated via 
oral route over a period of 28 days. So, it can be concluded that the Palagarai Parpam can 
be prescribed for long term therapeutic use in human with the necessary dosage reduction 
and can be used up to 250mg/kg. body weight p.o. 
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   PALAGARAI  (Cypraea  moneta) 
    HISTOPATHOLOGY 
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PHARMACOLOGICAL STUDY 
HEPATOPROTECTIVE ACTIVITY OF PALAGARAI PARPAM AGAINST 
CCL4 INDUCED HEPATOTOXICITY RATS 
 
INTRODUCTION 
 Liver diseases remain one of the most serious health problems. In view of severely 
undesirable side effects of synthetic agents and the absence of reliable liver-protective 
drugs in modern medicine, there are a number of medicinal preparations in the Siddha 
system of Indian medicine recommended for the treatment of liver disorders. Their usage 
has been popular for centuries and are quite often claimed to offer significant relief. Also, 
there is a growing trend to follow systematic research methodology and to evaluate the 
scientific basis for traditional medicines that are claimed to possess hepatoprotective 
potential.  
 As the efficacy of Siddha medicinal products in preclinical liver diseases is not 
well documented, accurate scientific assessment has become a prerequisite for acceptance 
of health claims. In the present study, an attempt has been made to study the effect of 
Palagarai Parpam in rats. Liver is the key organ regulating homeostasis in the body. It is 
involved with almost all the biochemical pathways related to growth, fight against 
disease, nutrient supply, energy production and reproduction. Because of its unique 
metabolism and relationship to the gastrointestinal tract, the liver is an important target 
for toxicity produced by drugs,  xenobiotics and oxidative stress. More than 900 drugs, 
toxins and herbs have been reported to cause liver injury and drugs account for 20-40% of 
all instances of fulminant liver failure.  
 In the absence of reliable liver protection drugs in modern medicine, a large 
number of medicinal preparations are recommended for the treatment of liver disorders 
and quite often claimed to offer significant relief. Attempts are being made globally to get 
scientific evidences for these traditionally reported Siddha drugs. This scenario provides a 
severe necessity to carry out research in the area of hepatotoxicity. 
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MATERIALS AND METHODS 
 
Drugs and chemicals 
Silymarin was a gift sample from Micro Laboratories, Hosur, India. Aspartate amino 
transferase (ASAT) and alanine amino transferase (ALAT), alkaline phosphatase (ALP) 
and total proteins (TP) kits were from RANDOX Laboratories Ltd. All other chemicals 
and reagents used were of analytical grade. 
 
Animals 
 Male Wistar rats weighing between 150 – 220 gm were used for this study. The 
animals were obtained from animal house, Department of Pharmacology, School of 
Pharmaceutical Sciences, Vels University, Tamilnadu, India. The animals were placed at 
random and allocated to treatment groups in polypropylene cages with paddy husk as 
bedding. Animals were housed at a temperature of 24±2oC and relative humidity of 30 – 
70 %. A 12:12 light: day cycle was followed. All animals were allowed to free access to 
water  and fed with standard commercial pelleted rat chaw (M/s. Sai durga foods, 
Bangalore). All the experimental procedures and protocols used in this study were 
reviewed by the Institutional Animal Ethics Committee and were in accordance with the 
guidelines of the IAEC. (Approval number:  XIII/VELS /PCOL/33/2000/C PCSEA/IAEC 
/ 08.08.2012). 
 
Hepatoprotective Activity: 
 A total of 30 animals were equally divided into 5 groups of six each.  
Group I: served as normal control received 0.5% (CMC) carboxy methyl cellulose 
solution (1 ml/kg) once daily (untreated);  
Group II: served as CCL4 control, administered with Carbon tetrachloride 3 ml / Kg.  
Group III: CCl4 + Palagarai Parpam (50mg/kg) treated animals;  
Group IV: CCl4 + Palagarai Parpam (100mg/kg) treated animals. 
Group V: served as reference control, received CCl4 + Silymarin (100mg/kg) once daily.  
                        All the test drugs and Standard were administered orally by suspending in 
0.5% CMC solution. After 48h of CCL4 administration and after the last dose of the test 
drugs, the blood was collected by retro orbital puncture under light ether anesthesia and 
serum was separated for the estimations of alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (ALP) and bilirubin.  
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Histopathological evaluation 
 At the end of the study, all the surviving animals of the respective groups were 
sacrificed by an overdose of ether anaesthesia. After exsanguinations of the animal’s liver 
were removed immediately and washed with ice-cool saline. The tissue samples were 
fixed with 10% formaldehyde, dehydrated in a graded series of ethanol, and embedded in 
paraffin wax before sectioning. The tissue was cut into sections approximately 5 μm 
thick, dewaxed, and rehydrated. The sections were then stained with haematoxylin-eosin 
dye and studied for histopathological changes using a light microscope. Each sample was 
observed at a magnification of 100X. 
 
Statistical Analysis: (Trial Drug 1 Chart 1-3) 
 The values were expressed as mean ± SEM. The statistical analysis was carried 
out by one way analysis of variance (ANOVA) followed by Dunnet’s ‘t’ - test. P values 
<0.05 were considered significant. 
 
RESULTS AND DISCUSSION 
 Carbon tetrachloride is a routinely used hepatotoxin for experimental study of 
liver diseases. Administration of CCl4 causes acute liver damage that mimics natural 
causes. It mediates changes in liver function that ultimately leads to destruction of 
hepatocellular membrane. Cytochrome P-450 activates CCl4 to form various free radicals 
(trichloromethyl, Cl3 C-CCl3 (hexachloroethane), COCl2 (phosgene), etc.) which are 
involved in the pathogenesis of liver damage in chain reactions resulting in peroxidation 
of lipids, covalent binding of macromolecules, disruption of metabolic mechanisms in 
mitochondria, decreasing levels of phospholipids, increasing triglyceride levels, inhibition 
of calcium pumps of microsomes thus leading to liver necrosis. Liver plays a major role 
in detoxification and excretion of many endogenous and exogenous compounds, any 
injury or impairment of its function may lead to several implications on one's health. 
Management of liver diseases is still a challenge to modern medicine.  
 Conventional drugs used in the treatment of liver diseases are often inadequate. It 
is therefore necessary to search for alternative drugs for the treatment of liver diseases to 
replace the currently used drugs of doubtful efficacy and safety. The hepatotoxic effect of 
CCl4 has been reported to be due to its metabolite CCl3º, a free radical that alkylates 
cellular proteins and other macromolecules. This study shows that hepatic injury induced 
by CCl4 caused significant rise in marker enzymes SGOT, SGPT, ALP and total bilirubin 
29 
 
.The serum enzymes like SGOT, SGPT, ALP and total bilirubin of treated animals were 
significantly reduced (p<0.01) by treatment of Palagarai Parpam at two dose levels 
50mg/kg and 100mg/kg , when compared with CCl4 treated control. From the result it is 
clear that the drugs show dose dependent activity. In histological studies, hepatocytes of 
the normal control group showed a normal lobular architecture of the liver. Whereas, the 
CCL4 treated group the liver showed hepatocytic necrosis and inflammation also 
observed in the centrilobular region with portal triaditis.  
 The Palagarai Parpam 50, 100mg/kg treated group showed minimal inflammation    
with moderate portal triaditis and their lobular architecture was normal. Silymarin treated 
group showed normal hepatocytes and their lobular architecture was normal. Since the 
changes associated with CCl4-induced liver damage are similar to that of acute viral 
hepatitis. The hepatotoxicity induced by CCl4 is due to its metabolite CCl3•, a free 
radical that alkylates cellular proteins and other macromolecules with a simultaneous 
attack on lipids, in the presence of oxygen, to produce lipid peroxides, leading to liver 
damage.  
 Amino transferases are present in high concentration in liver, an important class of 
enzymes linking carbohydrate and amino acid metabolism. Alanine amino transferase and 
aspartate amino transferase are well known diagnostic indicators of liver disease. In cases 
of liver damage with hepatocellular lesions and parenchymal cell necrosis, these marker 
enzymes are released from the damaged tissues into the blood stream. Alkaline 
phosphatase is a membrane bound enzyme and its elevations in plasma indicate 
membrane disruption in the organ. Alkaline phosphatases, although not a liver specific 
enzymes, the liver is the major source of this enzyme.  
 The level of this enzyme increases in cholestasis. Hepatotoxicity is characterized 
by cirrhotic liver condition which in turn increased the bilirubin release. Thus, In 
conclusion, the present study, the activities of these enzymes, total bilirubin were found to 
increase in the hepatotoxic animals, and were significantly reduced in groups of Palagarai 
Parpam administered rats as compared to that of toxicant rats. The effect was more 
pronounced with these dose levels of Palagarai Parpam confirms the dose dependent 
hepatoprotective action in rats.   
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Evaluation of antioxidant activity of Palagarai Parpam by beta-carotene bleaching 
method 
 The rapid evaluation of antioxidant activity of Palagarai Parpam was determined 
according to the beta-carotene bleaching method. In this procedure the Palagarai Parpam, 
Vit.E were applied on TLC plates and after developing with a suitable solvent system, 
plates were sprayed with a betacarotene solution and exposed to daylight until discoloring 
of the background (6h.) The active compounds were seen as orange color on the plate. 
Vit.E was used as positive control. Palagarai Parpam was showed strong antioxidant 
activity. The same experiment was repeated twice for confirmation. The developed TLC 
plate after spraying with the reagent of beta-carotene showed no discoloration of the 
background after 6 hours. 
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PHARMACOLOGY 
HISTOPATHOLOGY 
Control       Normal 
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ANTIOXIDANT ACTIVITY 
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    DISEASE ASPECT 
    SIDDHA ASPECT 
    fšäuš nehŒfŸ5 
ntWbga®fŸ : 
 ty¥gh£Ouš nehŒ, khªj¡ f£o, fškhªj«, a¡Fj« vd¥ 
bga®fS©L. 
 
ïašò : 
 ïa‰ifahf kh®ã‹ Ñœ ty¥g¡f« cŸs ty¥gh£Ouš, 
m¥g¡fKŸs filÉyh vY«ò tiuÆY« Ã‰fhkš j‹dsÉš 
nkY§ÑGkhf¥ bgU¤J¡ bfh©nl tUtJ«, j‹ ïa‰if¤ bjhÊiy 
ïH¥gJ«, mšyJ msÉš Äf¢ áW¤J¡ bfh©nl tªJ gy nehŒfisí« 
Jizah¡FtJkhd ïašig¥ bgW« nehah«. 
 
nehŒ tU« tÊ : 
1.   ÄFªj msÉš czití©zš, cl‰bfh›th¥ 
bghUŸfis¡ bfhŸsš,  
2.   fŸ, rhuha«, KjÈa ka¡f¤ij¤ jU« Fo tiffis msî 
flªJ Fo¤jš,  
3.   bg©fË‹ T£lhš tU« nehŒ M»t‰whY«, Ru« KjÈa 
nehŒf£F¤ Jizahfî« tUtjhF«. 
 
K‰F¿ : 
 thŒ if¤jš, RitÆ‹ik, thŒÚUwš, gáÆ‹ik, c©l czî 
brÇahik, fhiyÆš ã¤jkhf thªâahjš, Kf« RU§» Kf vY«ò 
vL¤J¡fh£lš, if fhš N«ã tÆW eh£FehŸ bgU¤J¡ bfh©nl 
tUjš, mo¡fo Ru§f fhŒjš v‹D« F¿fis¡ fh£o ty¥ gh£Ouš 
bgU¤J¡ bfh©nl tU«. 
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nehŒ v© : 
 F‰w msthf _‹W tif¥gL«.  mit tË¡ fšäuš nehŒ, mHš 
fšäuš nehŒ, Ia¡ fšäuš nehah«. 
 
tË¡ fšäuš nehŒ : 
1. clÈ‹ f© tË¡ F‰w« bgU»¤ jd¡F¤ Jizahf mHš 
F‰w¤ijí§ T£o, Ru¤ijí©lh¡», cliy ehS¡F ehŸ, 
ïis¡f¢ brŒí« 
2. tÆW bgU¤J¡ bfh©nl tUjš, ïur ehs§fË‹ Ko¢RfŸ 
fd¤J¤ bjhil ïL¡FfËY«, m¡FŸ, tÆW, fG¤J, kh®ò 
ït‰¿š njh‹W«. 
3. eh£ bršy¢ bršy¥ gL¡ifÆÈU¤â¤ J‹òW¤J«.   
4. nehŒ KâU§fhy¤âš  clÈ‹ FUâ FiwªJ clš btS¤J¡ 
fhš, if, tÆW M»aitfS« å§»¡ fhQ«. 
 
mHš fšäuš nehŒ : 
1. fšäuÈ‹ ïa‰if¢   braY§F‹¿¥ ã¤JÚiu clš KGikí« åá 
cliy kŠrŸ Ãwkh¡F«.   
2. thŒ if¤jš, ã¤J thªâahjš, KfŠ RU§fš, if fhš å§fš, 
FUâÆ‹ t‹ikÆ‹ikahš clš btS¤J¡fdhš v‹D§ 
F¿fis¡ fh£L«. 
3. bgU tÆW nehiaí« ã‹ bjhlu¢ brŒí«. 
 
Ia¡fšäuš nehŒ : 
1. fšäuš Äf¥ bgU¤J, bjhLif¡F¡ f£o K£oahf¡ fhz¥gL«.    
2. áWÚ® átªJ, msÉš FiwªJ ïÊí« 
3. kŠrŸ (fhkhiy) nehŒ, clš å§Fjš, clš btS¤jš  
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ÔU« Ôuhjit : 
 tË¡F‰w¤jhš tU« nehí« Ia¡F‰w¤jhš tUnehí« Ôuhjh«. 
 
bghJ¡Fz§fŸ : 
1. czÉš btW¥ò, eh¢Rita¿ahik, c©ÂD« thŒ Fk£o 
Fk£o  thªâahjš, fhiyÆš vGªj clnd thŒ Fk£o¥ 
ã¤JÚuhf thªâbaL¤jš, c©l czî« rÇtu brÇahâU¤jš.  
2. brÇ¥ãD« cl‰F C£lkË¡fhkš cliy ïis¡f¢ brŒjš, 
KfŠRU§Fjš, jhil vY«ò btË¤ njh‹wš  
3. if, fhš N«ã, clš btS¤J tÆW bgU¡f¤ bjhl§F«.  
fšäuY« ehS¡FehŸ bgU¤J¡ bfh©nl tU«. 
 
F‰w ntWghL : 
 mHš (ã¤j) F‰w¤jhbyGªJ jd¡F¤ Jizahf k‰w ïU 
F‰w§fis¡ T£o¡bfh©L guîfhÈ‹ braiy¡ bfL¤J tUnehah«. 
 
czî : 
 gá¤Ô Äfî« bfLkhjyhš fod czîfŸ vËâš brÇahjhifÆ‹ 
ïUKiw to¤j nrhW mšyJ fŠá tiffËš VnjD« x‹iw¡ 
bfhL¡fyh«.  f¤jÇ¥ ãŠr, g¥ghË¡fhŒ, KU§if¥ ãŠR, mtiu¥ ãŠR 
ngh‹wití« M£L¡f¿, fhil, bfsjhÇ, cL«ò, e¤ij e©L ït‰iw 
tH§fyh«.  Ñiu tiffSŸ KŸs§» áW Ñiu, KŸË¡Ñiu, griy¡Ñiu 
M»a ït‰iw¤ Jt£oí©zyh«. 
 fŠá tiffisí« btŸsh£o‹ f¿, fhil bfsjhÇ ït‰¿‹ 
FoÚ® (N¥ò), áWÑiu, bgh‹dh§fhÂ, fÇrhiy, f¤âÇ¥ãŠR, KU§if¥ 
ãŠR, Õ®¡F, òliy, btŸis¥ó©L, bt§fha«, g¥ghË¥ ãŠr ït‰iw 
c©zyh«. 
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MODERN  ASPECT 
Liver disease1 
 
Liver disease is invariably applied to many disease and disorder, which cause the 
liver to function improperly and may lead even to stop functioning . Abnormal  pain, 
yellowing of skin or eye (jaundice) or abnormal result of liver function test are the 
suggestion features of liver disease1. 
Usually liver disease classified as hepatocellular diseases, cholestastics 
(obstructive) or mixed.21 
 Hepatocellular diseases are viral hepatitis, alcoholic liver disease. In 
hepatocellular diseases the features of liver injury, inflammation, necrosis are 
predominant. 
 Cholestastic  diseases are gallstone, malignant obstruction, primary biliary  
cirrhosis, some drug -induced liver diseases. In this disease  features of inhibition of bile 
flow is predominate. 
 Mixed pattern liver diseases are cholestastic forms of viral hepatitis, many drug 
induced liver diseases.  In mixed pattern both hepatocellular and cholestastic injury 
present.  Liver  diseases are classified as acute and chronic liver diseases. 
 
Acute liver diseases:22 
Symptoms  :   
 This may asymptomatic and anicteric, symptomatic diseases, which is often viral, 
produces symptoms of malaise, anorexia, and fever. Jaundice may appear as illness 
progresses.  
Signs: 
· Jaundice  
· Enlarged liver  
· Pale stools  ( cholestastic) 
· Liver palms (severe acute liver diseases)  
· Dark urine 
· Spider navi 
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Chronic liver diseases 
Symptoms:  
 Patients may be asymptomatic or complain of non- specific symptoms, 
particularly fatigue 
Specific symptoms: 
· Right hypochondric pain 
· Abdominal distention 
· Ankle swelling 
· Pruritus 
· Breast swelling 
· Loss of libido 
· Amenorrhoea 
· Confusion and drowsiness 
Signs 
General sign: 
· ±Fever 
· ±Jaundice 
· Loss of hair 
Compensated Sign: 
· Xanthelamas 
· parotid enlargement 
· spider navi 
· liver (small or large) 
· spleenomegally 
· gynaecomastia 
· liver palms 
· scratch marks  
· purpura 
· testicular atrophy 
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De compensated sign 
· Neurological  i.e. disorientation 
· Drowsy 
· Hepatic flap 
· Coma 
· Ascites 
· Dilated veins on abdomen 
· ± Oedema  
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CLINICAL STUDY 
 STUDY DESIGN & CONDUCT OF STUDY. 
 Study place :  NIS (OPD,IPD) 
 Period          : 12 months 
 Sample size : 20 patients (both sex) 
 Weight         :  40-85 kg 
 Dose             :  130 mg with ghee or butter 
 Duration      : 30 days 
 
SUBJECT SELECTION: 
 Patients reporting at OPD of Ayothidoss Pandithar hospital with symptoms of 
inclusion criteria were subjected to screening test & documented using screening 
proforma. 
Inclusion criteria:   
             1.    Age       :20-60 years 
             2.   Sex         :both male and female 
             3.  Weight   :40-85 kg 
             4.  Patient having symptoms of 
Ø Malaise 
Ø Anorexia 
Ø nausea 
Ø vomiting 
Ø Jaundice 
Ø Upper abdominal pain 
            5.  Patient who are willing to provide blood for lab investigation. 
            6.  Patient willing to sign the informed consent stating that he/she will 
conscientiously stick to the treatment during 30 days but can opt out of the trial of his/her 
own conscious discretion. 
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Exclusion criteria: 
§ Cardiac disease 
§ Hepatic failure 
§ Pregnancy and lactation 
§ Any other serious illness 
 
Withdrawal criteria: 
                 1. Development of any adverse reaction  
      2. Occurance of any other serious illness 
TESTS AND ASSESMENTS 
A. Clinical assessment  
Siddha assessment 
B. Laboratory Investigations 
1. Routine investigations 
2. Specific investigations 
A.CLINICAL ASSESSMENT 
Ø Malaise 
Ø Anorexia 
Ø nausea 
Ø vomiting 
Ø Jaundice 
Ø Upper abdominal pain 
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5.  Patient willing to provide SIDDHA PARAMETERS 
1. Naa 
2. Niram 
3. Mozhi 
4. Vizhi 
5. Sparisam 
6. Naadi 
7. Malam 
8. Moothiram –Neerkuri and Neikuri     
 
 ROUTINE INVESTIGATION 
    BLOOD 
§ Hb (gm/dl) Total WBC Count( Cells/cumm) ,  
§ DC - (Polymorphs (%), Lymphocytes (%) Eosinophils(%) , Monocytes(%), 
Basophils (%),   
§ Total RBC count (Million cells / cu mm), 
§ ESR (mm/hr) 
§ Blood glucose ( mg/dl) ( Fasting, Post Prandial or Random) 
 
LIPID PROFILE 
§ Serum cholesterol (mg/dl), HDL cholesterol (mg/dl), LDL cholesterol (mg/dl)-
VLDL cholesterol (mg/dl), Serum triglycerides (mg/dl).    
KIDNEY FUNCTION TESTS 
§ Blood urea(mg/dl), Serum Creatinine (mg/dl) 
LIVER FUNCTION TESTS 
§ Serum total bilirubin (mg/dl) , Serum Direct bilirubin (mg/dl) , Serum Indirect 
bilirubin (mg/dl), Serum Alkaline phosphate (u/l) , SGOT (u/l), SGPT (u/l), 
Serum Total Protein   ( g/dl) , Serum Albumin( g/dl), Serum Globulin( g/dl), 
Serum Calcium (mg/dl), Serum Phosphorous (mg/dl), Serum Uric Acid (mg/dl). 
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URINE 
Urine sugar (F) & (PP) or (R), Albumin, Deposits Bile salts,Bile pigments, Urobilinogen. 
MOTION 
§ Ova, Cyst, Occult blood. 
OTHER INVESTIGATION 
§ USG Abdome 
Specific investigations:  
 Liver Function Test  
 Urine:  
  Bile salts  
  Bile pigments  
       STUDY ENROLLMENT:   
· In this clinical study, patients reporting at the OPD with the clinical symptoms of 
malaise, anorexia ,nausea ,vomiting ,jaundice ,upper abdomen pain etc will  be 
examined clinically for enrolling in the study based on the inclusion and exclusion 
criteria.  
· The patients who are to be enrolled would be informed (Form IV C) about the study, 
trial drug, possible outcomes and the objectives of the study in the language and terms 
understandable to them. 
· After ascertaining the patient’s  willingness, informed consent would be obtained in 
writing from them in the consent form (Form IV-A). 
· All these patients will be given unique registration card in which patients’ 
Registration number of the study, Address, Phone number and Doctors phone number 
etc. will be given, so as to report  easily should any complications arise. 
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· Complete clinical history, complaints and duration, examination findings-- all would 
be recorded symptoms in the prescribed Proforma in the history and clinical 
assessment forms separately. Screening Form- I will be filled up; Form I-A,  Form –II 
and Form –III will be used for recording the patients’ history, clinical  examination of 
symptoms and  signs and laboratory investigations respectively. 
· Patients would be advised to take the trial drug and appropriate dietary advice (Form 
IV-D) would be given according to the patients’ perfect understanding. 
 
CONDUCT OF THE STUDY: 
 
· Liver disease patient who satisfying the inclusion criteria will be admitted to the trial. 
· Patient informed consent will be obtained 
· For OP patients ,they should visit the hospital once in 7  days.  At each clinical visit 
clinical assessment is done and prognosis is noted.  
· For IP patients clinical assessment is daily and prognosis is noted. 
· Laboratory investigations  are done  before the trial started and at end of the trial  for 
both  
OP & IP patients    
 
CLINICAL OBSERVATION: 
 From the clinical study 75% of patient relieved from upper abdomen , relieved 
from vomiting,71% of patients relieved from  nausea,69 % of patients relieved from 
anorexia, 
63 % of patients relieved from malaise,65% of patients  relieved from jaundice and no 
adverse effects were observed during trial period.  
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DISCUSSION 
 
 The principle aim of this study was to assess the pre-clinical safety and efficacy 
and to evaluate the therapeutic efficacy of the drug Palagarai Parpam in the management 
of Kalleral Noi. 
 As per Siddha text, in Kalleral noi,  Pitham humours was deranged and then 
Vatham, Kabham Thathu were deranged. Pitham  is responsible for the functioning of 
digestion , maintenance of the blood environment (Udal Thathu - Senneer), appetite. 
Hence Pitha thathu when deranged produces symptoms like nausea, vomiting, malaise, 
and abdomen pain.23 
 The trial drug Palagarai Parpam possess  Kaippu suvai and Kaarppu veeryam, 
hence it balances the deranged  Pitha Kutram. In addition to this it also have sedative 
activity which exert the soothing effect.10 As per Siddha text Kaippu Suvai  detoxified the 
toxins,24 nowadays toxins are major cause of Kalleral noi (liver disease ). Hence 
administration of the trial drug Palagarai Parpam was effective in the management of 
Kalleral noi. 
Biochemical analysis: 
 Biochemical analysis of the drug Palagarai Parpam reveals the presence of 
Sodium, Calcium, Phosphate , Iron, and Alkaloids and Chloride. 
Calcium: 
 Calcium malabsorption has been demonstrated in primary biliary cirrhosis (PBC) 
and in hepato-cellular disease; this has been attributed to decreased intestinal absorption 
of vitamin D. 
Sodium:26 
  Important for acid-base balance. 
  Required for normal muscle irritability and cell permeability. 
  Sodium deficiency causes muscle cramps.  
   Sodium reduces prostaglandin synthesis.  
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Role of Alkaloid in treating Kalleral noi (liver disease ):  
 It possesses anti-oxidant property and causes induction of anti-oxidant enzymes 
like Superoxide dismutase and reduces glutathione & catalase. Also stimulates heme 
oxygenase – 1 activity. 
 
The preliminary phytoconstituents screening of the trial drug Palagarai Parpam 
was done by using  AAS The result shows the presence of  Zinc, Calcium, Magnesium. 
Magnesium:27 
It has antioxidant properties and is need to activate as number of enzymes, helps 
the body to absorb vitamin B, and vitamin E. Magnesium inhibit lipid peroxidation. 
Calcium:   
Importance of calcium supplement in liver disease 
Calcium malabsorption has been demonstrated in primary biliary cirrhosis (PBC) 
and in hepato-cellular disease; this has been attributed to decreased intestinal absorption 
of vitamin D 
Zinc:  
 Zinc supplement Prevent Liver disease.28 Zinc plays an important role in the 
protection of cell membrane integrity and may be protective against free radical injury. 
Zinc is needed for the functions of over 100 enzymes. It is essential for DNA, RNA and 
protein synthesis and, as such, is important for cell division. Recent reports indicate that 
in human subjects thymopoietin may be zinc dependent and in animal studies 
somatomedin   may be affected adversely due to dietary zinc restriction. 
The clinical features of cirrhosis of the liver, poor appetite, susceptibility to 
infections and enhanced sensitivity to drugs, may be related to conditioned deficiency of 
zinc.* 
AAS analysis of the drug Palagarai Parpam reveals the presence of Calcium, Zinc. 
Toxicologicological studies   
 The results indicated the toxic effect upto 500mg/kg of Palagarai Parpam treated 
via oral route over a period of 28 days. So, it can be concluded that the Palagarai Parpam 
can be prescribed for long term therapeutic use in human with the necessary dosage 
reduction and can be used up to 250mg/kg. body weight p.o. 
*(The role of zinc in gastrointestinal and liver disease.)Prasad AS) 
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Pharmacological  Studies 
In conclusion, the present study, the activities of these enzymes, total bilirubin 
were found to increase in the hepatotoxic animals, and were significantly reduced in 
groups of Palagarai Parpam administered rats as compared to that of toxicant rats. The 
effect was more pronounced with these dose levels of Palagarai Parpam confirms the dose 
dependent hepatoprotective action in rats.  
 
Clinical observation:  
 From the clinical study 75% of patient relieved from upper abdomen , relieved 
from vomiting,71% of patients relieved from  nausea,69 % of patients relieved from 
anorexia, 
63 % of patients relieved from malaise,65% of patients  relieved from jaundice and no 
adverse effects were observed during trial period.  
 Total bilirubin level  significantly reduced for 72% of patients. 
 SGOT level  reduced significantly for 83% of patients. 
 SGPT level reduced  significantly  83% of patients. 
  
Bio-statistics: 
              Statistically, the paired ‘t’ test shows statistical significance for the symptoms 
before and after the treatment.(p<0.0001). 
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SUMMARY 
 
The literary evidence strongly supports the hepatoprotective activity of Palagarai 
Parpam. The literary evidence from  Kannusamy parambarai Vaithiyam strongly support 
the hepatoprotective activity of the drug.  
 
The qualitative and quantitative analyses were done at Biochemistry lab, NIS and 
SRU, Chennai respectively. The biochemical analysis of the drug reveals the presence of  
zinc, magnesium, calcium, alkaloid, amino acids. The results ensure the Hepatoprotective 
and Antioxidant  activity of the Palagarai Parpam was due to the presence of active 
phytoconstituents of the drug.  
 
The pre-clinical evaluation (acute & repeated oral toxicity study) of the drug was 
carried out as per OECD guideline in Vels college of pharmacy, Chennai. The result 
shows safety of the drug   for human administration. 
 
The Preclinical Pharmacological study was carried out in animal model in Vels 
college of pharmacy, Chennai. The result shows that the drug has significant 
hepatoprotective activity.  
 
As per the Siddha literature and modern science reviews and research articles, the 
trial drug has potent Hepatoprotective  effect.20 Patients were recruited for clinical trial.  
The trial drug hepatoprotective activity  at the dose of 130 mg, bid was given to the 
patient for 7 days and patients were asked to visit op once in 7 days for 30 days. Clinical 
assessment and prognosis was noted at each visit.  
 
  From the clinical study 75% of patient relieved from upper abdomen , relieved 
from vomiting,71% of patients relieved from  nausea,69 % of patients relieved from 
anorexia,63 % of patients relieved from malaise,65% of patients  relieved from jaundice 
and no adverse effects were observed during trial period.  
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 Total bilirubin level  significantly reduced for 72% of patients. 
 SGOT level  reduced significantly for 83% of patients. 
 SGPT level reduced  significantly  for 83% of patients 
 The drug Palagarai Parpam. has 
 
§ Hepatoprotective activity.and Antioxidant Activity. 
§ No side effects  
§ No undoing effects 
§ Encouraging clinical resultsFrom the clinical and the statistical analysis, it is proved 
that the drug Palagarai Parpam is statistically significant on Hepatoprotective activity 
on Kalleral noi. 
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CONCLUSION 
 
Ø The literature and research journal review of the herbo mineral drug  shows that it 
has hepato-protective activity. 
 
Ø The safety studies (acute toxicity and sub-acute l toxicity) studies conducted 
revealed that the trial drug palagarai parpam is safe. There were no abnormalities 
found in blood investigation and histo-pathological examination. Hence it can be 
reasonably assumed that the drug is safe for human use. 
 
Ø The pharmacological study conducted in animal model shows significant hepato-
protective activity. 
 
Ø Clinical study revealed the therapeutic efficacy of the trial drug by showing, 
reduction in serum enzyme markers SGOT, SGPT level ,Total bilirubin level 
significantly. There was improvement in other clinical symptoms before and after 
treatment. 
 
Ø There were no adverse reactions complained during the clinical trial. 
Hence, the drug Palagarai Parpam can be used in the management of Kalleral noi  
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INTRODUCTION 
 
Soolai (Osteoarthritis-OA) is characterized  by focal loss of articular cartilage and 
proliferation and remodelling  of bones around the joint to form osteopyte. Inflammation 
can be a feature of Osteoarthriti.29 
Osteoarthritis (OA) represents an imbalance in destruction and synthetic process 
of the cartilage lead to the erosion, decreased concentration and viscosity of the synovial 
fluid, decreased lubricating and cushioning properties. There is also an underlying 
inflammation of the synovium as well as damage in the subchondral bone. 
Several factors predispose to the disease and accelerate its progression. These 
includes pre-existing  joint diseases, obesity, hyper mobility, orthopedic  deformity, 
endocrine disorder like diabetes mellitus, hyperparathyroidism. Overuse of joints and 
adoption of unusual posture for long periods predispose to the condition.   
Among  the elderly, Knee Osteoarthritis is the leading  cause of disability in 
developed country.21 
Osteoarthritis (OA) affects 10-15% of world population.30  About 5.7% of  
Population of India has  Osteoarthritis  (OA).31 In general prevalence of osteoarthritis 
increases with age. 80% of people affected by 40 years. More than 50% have bilateral  
Osteoarthritis.32 Women have great tendency than men.32 Genetic tendency in knee 
Osteoarthritis is twice as  that of  osteoarthritis hip. 
Chithiramoola  Rasayanam is mentioned in  Siddha literature, Pulipanivaithiyam 
500  for Soolai. Soolai generally means deep seated pain.33 Such a pain  is experienced in 
arthritis. As per  Siddha  text  Soolai  means  Soolam  ennum   karuviyal  kuthungal 
undakum valiyaiyottha noi.6    
  Rasayana means  a medicine, which  prolongs  life and  neutralise  deranged 
Vatham, Pitham, Kapham. Soolai is caused by deranged Vatham33. The sage  Therayar  
has quoted that "Nedu vatha sarvathumandri Soolai varathu".6  
Hence the author selected Chithiramoola  Rasayanam for Anti-inflammatory activity in 
the management of Soolai. 
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AIM: 
To evaluate the safety and efficacy of Chithiramoola Rasayanam  for   anti-
inflammatory activity in the management of  Soolai (Osteoarthritis).34 
 
OBJECTIVE: 
 
Primary objective: 
To evaluate the Anti-inflammatory activity of “Chithiramoola Rasayanam” for 
Soolai (Osteoarthritis) in preclinical studies. 
 
Secondary objectives: 
 Biochemical analysis 
 To evaluate the efficacy of Chithiramoola Rasayanam in the management of 
Soolai (Osteoarthritis) 
 High performance thin layer chromotography 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
52 
 
MATERIALS AND METHODS 
STANDARD OPERATIVE PROCEDURE: 
 
COLLECTION AND AUTHENTICATION OF RAW DRUGS: 
The raw drug was procured from Ramasamy chetty shop Paris Chennai and 
authenticated by competent authority of  department of Gunapadam, National institute of 
Siddha. 
 
INGREDIENTS: 
 Purified Chithiramoolam (Plambago indica)- 30 palam(1050 gm)  
 Purified Nilappanai (Curculigo orchiodes)- 30 palam (1050gm) 
 Purified Thannirvittan (Asparagus racemosos)- 30 palam(1050 gm) 
 Purified Parangichakkai (Smilax china)_30 palam (1050 gm)  
 Purified Cherangkottai (Semecarpus anacardium)-40 palam(1400 gm)  
 Honey- 80 palam (2800 gm)  
 Ghee -80 palam (2800 gm) 
 Vellai Sarkarai (Saccharum officinarum)-160 palam ( 5600 gm) 
Purification  process: 
 Purification of Chithiramoolam35: 
  The outer covering was powdered and then baked in milk steam for 3 
hours and then powdered . 
 Purification of Nilappanai36: 
  The drug was powdered and baked in milk steam for 3 hours, then dried in 
sunlight and powdered . 
 Purification of Thannirvittan36: 
  The drug was powdered and baked in milk steam for 3 hours, then dried in 
sunlight and powdered .  
  Purification of Parangichakkai36: 
  The drug was powdered and baked in milk steam for 3 hours, then dried in 
sunlight and powdered.  
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 Purification of Cherangkottai37: 
Cut the nose like projection of seed and boiled with cow dung’s  solution. Repeat 
the procedure for 7 times. 
Method of medicine preparation35: 
Purified Chithirmoolam, Purified Tannirvittan, Purified Nilappanai, Purified 
Parangichakkai, Purified Cherangkottai are dried well and pulverized by an electric 
grinder into fine  powder  and then was sieved by using a fine silk cloth (vasthra kaayam)  
and then mixed with sugar, honey and ghee. The outcome of Rasayanam stored in a clean 
dry airtight glass bottle. 
 
LABELLING: 
 Name of the preparation : Chithiramoola Rasayanam   
 Quantity of the drug  : 70gm 
 Dose    :5 g bid  
 Adjuvant or Vehicle  :  -  
 Indication   : Soolai (osteoarthritis)  
 Date of manufacturing            : The drug was prepared in two batches 
                                                                       5/4/12, 5/8/12 
            Expiry                         :6 months from the date of manufacture. 
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    bfhontÈ               gw§»¥g£il  
   Plumbago zeylanica    Smilax China.Linn 
 
 
                                 
j©Ù® É£lh‹        Ãy¥gid                   
Asparagus racemosus    Curculigo orchioides.Gaertn                                        
              
nruh§bfh£il 
Semecarpus anacardium.Linn. 
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CHITHIRAMOOLA    RASAYANAM    
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REVIEW OF THE LITERATURE 
 
GUNAPADAM ASPECT6  
   bfhontÈ ( Plumbago zeylanica) 
ntWbga® :  bfhLntÈ, á¤âu_y«, á¤âu«, t‹Å 
ga‹gL« cW¥ò : nt®, g£il 
Rit :  fh®¥ò, ÉWÉW¥ò  , j‹ik: bt¥g«  ,ãÇî : fh®¥ò. 
brŒif :  Kiwbt¥gf‰¿, Éa®ití©lh¡» 
bghJFz« : 
 ïjdhš, f£o, ò©, fHiy, tËnehŒ, miuah¥ò¡f£o, F¤jš, nrhig, 
_ynuhf«, câu¡f£L, Únu‰w«, bgUtÆW ïitngh«. 
 “f£oÉu z§»uªâ fhšfŸ miuah¥ò¡ 
 f£o¡N iyå¡f§ fhœ_y« - K£ou¤j¡ 
 f£LÚ nu‰w§ fd¤j bgUtÆW« 
 m£L§ bfhontÈ ah«.” 
 
   Ãy¥gid (Curculigo orchioides.Gaertn) 
ntWbga®: thuh», KrÈ, jiy¤jhJ, nea«, á¤â 
ga‹gL« cW¥ò :  »H§F, nt® 
Rit :  ïÅ¥ò ,j‹ik :  j£g« ,ãÇî : ïÅ¥ò. 
brŒif : cukh¡», mf£Lthaf‰¿,  
Fz« : 
 ïjdhš, ÚÇÊî, bt¥g«, bt©òŸË, fU«òŸË, Éyh¡F¤jš, xG¡F 
btŸis, f©nehŒfŸ ïit ngh«. M©ikí©lhF«. 
 “nkf tsdšjÂí« bt©F£lª jh‹ÉyF« 
 nghf ÄfîKW« bgh‰bfhona! - nghfhj 
 Niynk f§fnshL J‹DfU« òŸËí« nghŠ 
 rhy Ãy¥gid¡F¤ jh‹” 
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j©Ù®É£lh‹ (Asparagus racemosus Willd) 
ntWbga® : j©Ù®É£lh‹, rjhntÈ, rjhntÇ, Ú®É£lh‹ 
ga‹gL« cW¥ò : ïiy, »H§F 
Rit :  ïÅ¥ò     j‹ik :  bt¥g«   ãÇî  :  ïÅ¥ò 
brŒif : clYukh¡», cŸsHyh‰¿, fhk«bgU¡» 
Fz« : 
 ïj‹ »H§F ÚÇÊî, eh£g£lRu«, vY«òU¡» nehŒ, btªÚiu mÊ¡F« 
nehŒ, bt£il, c£NL KjÈat‰iw Ú¡F«. 
 
    gw§»¥g£il (Smilax China.Linn) 
ntWbga®:  kJÞÄf«, kJÞÛ», Ód¥g£il, gw§»r¡if 
ga‹gL« cW¥ò : »H§F 
Rit :  ïÅ¥ò,  j‹ik :  bt¥g«,  ãÇî : ïÅ¥ò, 
brŒif : cl‰nw‰¿, nkf¥ãÂÉy¡», fhk«bgU¡», öŒikah¡» 
Fz« : 
 ïjdhš Ú®nt£if, g‰gy tËnehŒ, ò©, ãsit, ÚÇÊî, foÉl«, 
áu§F, _yKis, Klthj«, FiwnehŒ, Ia«, kfuªj¥ò©, thªâ ïit Ú§F«. 
M©ik c©lh«. 
 “jhf« gythjª  jhJe£l« ò©ãsit 
 nkf§ fo»uªâ åœ_yª - njfKl‹ 
 F£il gfªjnk‰ bfhŸtkd« ngh«gw§»¥ 
 g£ilÆid í¢rÇ¤J¥ gh®.” 
 
   nruh§bfh£il (Semecarpus anacardium.Linn) 
ntWbga® :   nr§bfh£il, tšyhâ, tšyhj», vÇK», gšyhj», »£lh¡fÅ¡ 
bfh£il, eªâÉ¤J 
ga‹gL« cW¥òfŸ :  bfh£il, gU¥ò 
Rit :  if¥ò, ÉWÉW¥ò,    j‹ik : bt¥g«,    ãÇî :  fh®¥ò. 
brŒif : cl‰nw‰¿, ò©zh¡» 
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Fz« : 
 “F£l§ fanuhf§ bfhšY« Élghfª 
 J£lª jU»UÄ Niyí« ngh« - k£lyU§ 
 Tªj‹kÆ ny»uªâ¡ T£l« nghŠ br§ifÆš 
 VªJnr§ bfh£iljid na.” 
 ïJ bgUnehŒ, ïis¥ò nehŒ, eŠRfŸ, Niy ïitfis¥ ngh¡fo¡F«.  
nkY« âÄ®¥g£il, fU¥ò¥ gil, bt©gil (bt© F£l«), Ôuh¡fo, _y«, 
tË nehŒfŸ, F‹k« ïitfisí« Éy¡F«. 
 
    nrU« kUªJfŸ  
á¤âu _y« nrU« kUªJfŸ : 
á¤âu _y beŒ : 
   msî                ; fu©oasî    
   ÔU« nehŒfŸ :  Niy, F‹k« 
   Mjhu«             : mf¤âa KÅt® mUË¢brŒj it¤âa  
             u¤âd RU¡f« 360 
kJÞÄ» urhaz« :  
   msî               :  gh¡fsî, ïUntis 
   ÔU«nehŒfŸ ; Niy, thjnehŒfŸ 
   Mjhu«           : mf¤âa KÅt® mUË¢brŒj it¤âa  
         u¤âd RU¡f« 360,  g. 40 
Niy¡ »ahH« : 
  ÔU«nehŒfŸ : Niy 
  Mjhu« : f©QrhÄ gu«giu it¤âa«  g. 71 
thj Ru »ahH« : 
  ÔU«nehŒfŸ : if fhš Fil¢rš, Niy 
  Mjhu«        ;  mf¤âa® KÅt® mUË¢ brŒj it¤âa u¤âd  
    RU¡f« 360, g. 111  
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Ãy¥gid »H§F nrU« kUªJfŸ : 
gw§» urhad« : 
 msî : fH‰ábfh£ilasî 
 ÔU« nehŒfŸ : Niy 
 Mjhu« : f©QrhÄ gu«giu it¤âa«  g. 461 
fªjf urhad« : 
 msî          : fH‰ábfh£il   mªâ, rªâ 
 ÔU« nehŒ : Niy 
 Mjhu«       : f©QrhÄ gu«giu it¤âa« 
j©Ù®É£lh‹ »H§F nrU« kUªJ :  
 euá«kny»a« 
   msî   : 5-10  »uh« 
  ÔU«nehŒfŸ: thj« 
   tH¡F: j©Ù® É£lh‹ »H§»‹ ïur«, nj‹ nr®¤J Fo¤J tu Niy Ú§F« 
Mjhu« : Fzghl« -Kjš ghf«. 
gw§»¥g£il nrU« kUªJfŸ : 
nkfthíÉ‰F »ahH« 
 ÔU«nehŒfŸ : Fil¢rš 
 Mjhu« :  f©QrhÄ gu«giu it¤âa«  g. 460 
gw§» urhad« : 
  msî                : fH‰á bfh£ilasî, mªâ, rªâ 
  ÔU« nehŒfŸ : Niy, nkfthí  
  Mjhu«             :  f©QrhÄ gu«giu it¤âa«  g. 461 
gw§» urhad« ; 
  msî              : btUfoasî 
  ÔU«nehŒfŸ : gâbd‹ Niy 
  Mjhu«          : nghf® it¤âa« 700 
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nruh§bfh£il nrU« kUªJ 
ïurfªâ bkGF : 
 msî : R©il¡fhŒ msî 
 ÔU« nehŒfŸ : thj Niy, fhš Fil¢rš 
 Mjhu« : á¤j it¤âa âu£L 
ïotšyhâ : 
 msî : R©ilasî 
 ÔU« nehŒfŸ : Niy 
 Mjhu« : á¤j it¤âa âu£L 
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BOTANICAL  ASPECT17 
    bfhontÈ  
BOTANICAL  NAME : Plumbago  zeylanica Linn 
VERNACULAR NAME: 
  ENGLISH            : Ceylon leadwort 
  SANSKRIT       : Chitraka 
  HINDI                  :Chita 
  TELUNGU          :Aagnimatu 
  MALAYALAM :Thumbu kodiveli 
CLASSIFICATION : 
  Kingdom:Plantae  
   Order    :Caryophyllales  
  Family   :Plumbaginaceae  
  Genus   :Plumbago  
        Species: P. zeylanica 
  Binomial name: Plumbago zeylanica Linn 
BOTANICAL DESCRIPTION:  
   Perennial,  sub-scandent  shrub ,160-120cm high. Leaves alternate, 
ovate, acute, glabraous, entire, stalk short, flower white, in bracteate, often branched, 
glandular and elongated spikes, 10-30cm long. Capsule  oblong, pointed, contained  in 
viscid, glandular, persistent calyx. seeds oblong. 
PARTS USED:  
  Roots, root bark.   
PHYSICAL CONSTANTS: 
  Foreign matter               - not more than 30%. 
  Total ash                         -not more than 3% 
  Acid insoluble ash          -not more than 1% 
  Alcohol extractive          - not less than 12% 
  water soluble extractive -not less than 12% 
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CHEMICAL CONSTITUENTS: 
  plant contains number of naphthoquinone derivatives  viz plumbagin,3-
chloroplumbagin , 3,3-plumbagin,plumbaginic acid , zeylinone. 
PHARMACOLOGICAL ACTIVITIES: 
  Antipyretic, Antitumour, uterotonic 
 
     Ãy¥gid 
BOTANICAL  NAME: : Curculigo orchioids 
VERNACULAR NAME: 
  ENGLISH            :Black musale 
  SANSKRIT       :Musale 
  HINDI                  : Musli 
  TELUNGU          : Nelatatigadda 
  MALAYALAM : Nilappana  
CLASSIFICATION  
  Kingdom:Plantae  
  Order:Asparagales  
  Family:Hypoxidaceae  
  Genus:Curculigo  
  Species:C. orchioides  
        Binomial name : Curculigo orchioids 
BOTANICAL DESCRIPTION: 
  Perennial,10-35cm high, root stocks stouts, short or elongated, cylindric, fleshy. 
PARTS USED: Root stocks 
CHEMICAL CONSTITUENTS: 
  Curculigosaponins, Curculigosides, Palmetic, Oleic, Linolenic, Linoleic, 
Flavoneglycosides. 
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PHARMACOLOGICAL ACTIVITIES:  
 Anti inflammatory, hypo glycaemic, hepatoprotective, flavanone glycoside 
showed powerful uterine stimulant. 
 
j©Ù®É£lh‹ 
BOTANICAL  NAME: Asparagus racemosus Willd. 
VERNACULAR NAME: 
 ENGLISH            :Wild asparagus  
 SANSKRIT       : Shatavari 
 HINDI                  : Satamuli 
 TELUNGU          : Satavari 
 MALAYALAM :  Satavari  
CLASSIFICATION  
 Kingdom      : Plantae  
 clade            :Angiosperms  
 clade         : Monocots  
 Order           : Asparagales  
 Family         : Asparagaceae  
 Subfamily     : Asparagoideae  
 Genus            : Asparagus 
 Species          : Asparagus racemosus  
 Binomial name : Asparagus racemosus 
BOTANICAL DESCRIPTION:  
Scandant, much branched spinous undershrub with tuberous, ,short root  stocks 
bearing numerous fusiform tuberous root, 30-100cm long and 1-2cm thick. 
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PARTS USED:  
 Tuberous root 
CHEMICAL CONSTITUENTS:   
 Sarasapogenin, saponin  A4-A7, diosgenin, asparagamine  and disaccharide in 
roots. Isoflavones, racemosol, polysaccharides, mucilage . 
 
PHARMACOLOGICAL ACTIVITIES: 
 Phagocytic, Anti-dysentry, gastric sedative, diuretic.     
    
gw§»¥g£il 
BOTANICAL  NAME: Smilax china Linn  
VERNACULAR NAME: 
 ENGLISH            : China root 
 SANSKRIT       : Dwipathru 
 HINDI                  :Chobchin 
 TELUNGU          : Galichekkai 
 MALAYALAM : Chinapaivu  
CLASSIFICATION  
 Kingdom:Plantae  
 Order:Liliales  
 Family: Smilacaceae  
 Genus:Smilax  
 Species:S.china  
 Binomial name : Smilax china 
PARTS USED: Root 
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CHEMICAL CONSTITUENTS: 
Fat , sugar, glucoside, saponin, steroidal saponins, phytosterols, triterpenoids (British 
Herbal Pharmacopoeia, 1983)  
Parillin -the antimicrobial and anti-tumoral activities (Bérdy et al., 1982)  
Sieboldogenin  
PHARMACOLOGICAL ACTIVITIES: 
 Alterative 
Antisyphilitic 
Aphrodisiac 
Depurative 
 
   nruh§bfh£il 
BOTANICAL  NAME: Semicarpus  anacardium Linn  
VERNACULAR NAME: 
 ENGLISH            :Marking nut 
 SANSKRIT       :Bhallataka-Bijam 
 HINDI                  :Bhilawa   
 TELUNGU          :Nallajidi  
 MALAYALAM : Chera 
CLASSIFICATION 
 Kingdom: Plantae  
 Order: Asparagales  
 Family: Asparagaceae  
 Subfamily Asparagoideae  
 genus: Asparagus 
 Species: Asparagus racemosus  
 Binomial name : Semicarpus  anacardium Linn 
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BOTANICAL DESCRIPTION: 
 A moderate sized , deciduous tree,12-15m high. leaves simple, 17.5-60cm long 
and 5-20cm broad, obvate- oblong ,glabrous above , ashy grey or buff and pubescent 
beneath .Drupes 2-3cm long, obliquely ovoid, smooth, shining, black when ripe, situated 
on fleshy orange coloured receptacle. 
PARTS USED: Fruit 
PHYSICAL CONSTANTS:   
  Total ash- not more than 4%,Acid insoluble ash -not more than0.51%, 
Alcohol extractive - not less than 11%,water soluble extractive -not less than 5%. 
 
CHEMICAL CONSTITUENTS:  
  Bhilawanol, anacardic acid, biflavonoids, essential amino acid-arginine, 
leucine, lysine. 
 
PHARMACOLOGICAL ACTIVITIES: 
  Anti-inflammatory, Analgesic, Anti-arthritic, Immunomodulatory,  
Hypocholesterolemic. 
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SUPPORTIVE JOURNALS: 
 Plumbago zeylanica: 
 The pharmacological results of our current studies revealed that Plumbagin 
elicited significant anti-inflammatory activities in the carrageenan model in both 
prophylactic and therapeutic schemes. In  present study ,the first evidence showing the  
anti-inflammatory and analgesic effects of plumbagin  in vivo through inhibition of NF-
κB activation*.  
· The pharmacological results of our current studies revealed that Plumbagin 
elicited significant anti-inflammatory activities in the carrageenan model in 
both prophylactic and therapeutic schemes.  
· keien ko (1931) find plumbagin stimulate CNS it in small dose but large dose 
paralysis occurs 
· Plumbagin reduce obesity.14  
 
Curculigo orchioides 
The root tubers of  Curculigo orchioides are a potent source of antioxidative 
phenolic compounds that counteract with ROS responsible for delayed wound healing, 
and speed up wound healing mechanism. The root tubers of Curculigo orchioides 
significantly increased the level of SOD, NO and decreased LPO in granuloma tissue of 
diabetic Mice.**  
Asparagus racemosus: 
It have rich potassium that intervenes in the elemination of corporal liquid and in other 
very interesting process as bony calcification.***  
The enzyme activity is also restored due to the presence of enriched therapeutic 
phytoconstituents which improve the indices of oxidative stress related to aging (Velavan 
and Begum, 2007a). 
 
 *Anti-inflammatory and analgesic effect of plumbagin through inhibition of nuclear factor-kappa B activation        
PEI LUO , YUEN FAN WONG , LIN GE, ZHI FENG ZHANG, YUAN LIU, LIANG  IU, HUA ZHOU Centre for Cancer and Inflammation Research, 
School of Chinese Medicine, Hong  Kong Baptist University, Kowloon Tong, Hong Kong (P.L., Y.F.W., L.G., L.L., H.Z.) Ethnic Pharmaceutical 
Institute, Southwest University for Nationalities, Chengdu, Sichuan Province, P.R. China (Z.F.Z., Y.L.) 
**Wound healing activity of standardized extract of Curculigo orchioides Gaertn in 
streptozotocin-induced diabetic mice (Pubmed) 
 
*(www.botanical-online.com)  
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Semecarpus anacardium* 
Ramprasathet et al. investigated the Anti-inflammatory effects of Semecarpus 
anacardium  nut extract on developing and developed adjuvant arthritis. Semecarpus anacardium 
significantly decreased the carrageenan-induced paw edema and cotton pellet granuloma. These 
results indicate the potent Anti-inflammatory effect and therapeutic efficacy of Semecarpus 
anacardium  Linn. Nut extract against all phases of inflammation is comparable to that of 
indomethacin. 
 
            Salvem et al. investigated that ethyl acetate extract of Semecarpus anacardium  led to the 
isolation of major active principle, tetrahydroamentoflavone (THA), a biflavonoid. The in vitro 
cyclooxygenase (COX-1)-catalyzed prostaglandin biosynthesis assay of THA gave an IC50 value 
of 29.5 μM (COX-1) and 40.5% inhibition at 100 g/mL (COX-2). The in vivo carrageenan-
induced paw edema assay resulted in dose-dependent Anti-inflammatory effect of THA and the 
activity was comparable to that of ibuprofen.  
 
 Bhitre et al. prepared the methanolic, ethanolic, chloroform, ethyl acetate and petroleum 
ether extracts of fruits of  Semecarpus anacardium   and tested to study the Anti-inflammatory 
activity using the technique of carrageenan-induced paw edema in albino rats. The extract showed 
significant Anti-inflammatory activity comparable to the reference standard aspirin.  
Smilax china 
 
 The aqueous extract of Smilax china is evaluated  for the inhibition of 
prostaglandin production (for COX-2 inhibitions) in lipopolysaccharide (LPS)-induced 
mouse macrophage cells. The result showed that both COX-2 activity and COX 
expression were inhibited by the extract***  
 It also exhibited significant inhibition of carrageenan-induced hind paw oedema at 
the doses of 10 and 50mg/kg. Computational molecular docking showed its molecular 
interaction with important amino acid residues in the catalytic site of lipoxygenase, 
revealing its potential binding mode at molecular level 
 
* A review  of  Semecarpus anacardium  
**Anti-inflammatory activities of Sieboldogenin from Smilax china Linn.: Experimental and computational studies. 
Inamullah Khan, Muhammad Nisar, Farooq Ebad, Said Nadeem, Muhammad Saeed, Haroon Khan, Samiullah, 
Fazli Khuda, Nasiara Karim, Zia Ahmad Department of Pharmacy, University of Peshawar, Peshawar 25120, 
Pakistan.  
***Journal of Ethnopharmacology (impact factor: 3.01). 11/2008; DOI:10.1016/j.jep.2008.10.009. 
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PHYSICAL PROPERTIES 
 
Materials and Methods 
The Physical properties of Chithiramoola Rasayanam were analysed in the 
following procedure done in Sri Ramachandra University. 
pH at 10% of aqueous solution: 
Five grams of Chithiramoola Rasayanam was weighed accurately and placed in 
clear 100 ml beaker. Then 50 ml of distilled water was added to it and dissolved well. 
After 30 minutes it was then applied in to pH meter at standard buffer solution of 
4.0,7.0,9.2.  
Ash Values 
 The Ash values measure of the inorganic constituents present in the raw drug.  A 
high ash content explains its unsuitable nature to be used as a drug . 
 
Total Ash 
 A little of extract was taken in a silica crucible previously ignited, cooled and 
weighed. It was incinerated by gradually increasing the heat not exceeding dull red heat 
(450°C) until free from carbon, cooled and weighed. The percentage of ash 
was calculated with reference to air- dried drug. The procedure was repeated to get the 
constant weight.  
 
Water soluble ash 
 The total ash was boiled with 25 ml water and filtered through ash less filter paper 
(Whatmann 4.1). It was followed by washing with hot  water .The  filter paper  was dried  
and ignited in the silica crucible, cooled and the water insoluble ash was weighed. The 
water-soluble ash can be calculated by subtracting the water insoluble ash from the total 
ash.  
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Acid insoluble ash 
 The total ash obtained was boiled for 5 minutes with 25 ml of (10% w/v) dilute 
hydrochloric acid and filtering through ash less filter paper (Whatmann 4.1).  The filter 
paper was ignited in the silica crucible, cooled and insoluble ash was weighed. 
 
HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY 
 
Significance of HPTLC fingerprinting in Standardisation 
Standardisation of traditional medicine has become mandatory in the present 
national and international scientific scenario, as they have to stand competing with 
stringent regulatory methods and also clinically. HPTLC is one of the versatile 
chromatographic methods presently available for the rapid analysis of herbal drugs due to 
several reasons. Firstly the time required for the demonstration of the most of the 
characteristic constituents of a drug is very quick and short. Secondly, in addition to 
qualitative detection, HPTLC also provides semi-quantitative information on the major 
active constituents of a drug, thus enabling an assessment of drug quality. Thirdly the 
fingerprint obtained is suitable for monitoring the identity and purity of drugs and for 
detecting adulteration and substitution. Hence in order to check the identity, purity and 
standardise the quantity of active principles in the herbal extracts a HPTLC fingerprint 
used in the formulation has been obtained.       
 
The distribution of phyto-constituents in a plant depends on various factors such 
as soil, time of collection period of storage, etc. So, it is necessary to standardize the 
extract being used for pharmacological studies. HPTLC serves as a convenient tool for 
finding out the distribution pattern of phyto constituents which is unique to each plant. 
The HPTLC finger-printing profile establishes the identity and purity of the raw drug 
being used. It helps in the authentification of the plant material.  
 
Chromatographic Conditions 
 The finger printing has been done using the following chromatographic 
conditions. Chromatography was performed on a10x10 cm pre activated HPTLC silica 
gel 60F 254 plate. Samples were applied to the plate as 6mm wide band with an 
automatic TLC applicator Linomat 5 with N2 flow (CAMAG, Switzerland), 8mm from 
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the bottom. Densitometric scanning was performed on CAMAG scanner III.The plates 
were pre-washed by methanol and activated at 600 C for 5 minutes prior to 
chromatography. The slit dimension was kept at 5 minutes x 0.45 minutes and 20 minutes 
scanning speed was employed. The mobile phase was chosen after running each plant in 
different mobile phases of varying polarity (Toluene, Toluene: Ethyl acetate and Ethyl 
acetate: Methanol) and 10 ml of mobile phase was used per chromatography. Linear 
ascending development was carried out in 20 cm x 10-em twin glass chamber saturated 
with the mobile phase.  
 
Chromatographic Analysis 
 The hydro alcoholic extracts of the plants have been prepared at a concentration of 
10 mg/10 ml in alcohol and were spotted using CAMAG Linomat 5 applicator. The 
method was optimized by selecting appropriate mobile phase for respective plant extracts 
and developed in a twin trough chamber, 20 x 10 cm at 25°C. The plates were dried by 
hair dryer. The developed plates were scanned at appropriate wavelength using CAMAG 
TLC scanner 3 and photo-documented using CAMAG REPROSTAR 3. 
 
Inferences 
The finger-printing profile establishes the identity and purity of the raw drug 
being used. It helps in the authentication of the respective plant material. The finger-
printing pattern is characteristic of each plant material used for pharmacological studies. 
The pattern clearly displays the variation from plant to plant. 
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HPTLC Fingerprint - RH1 
 
Sample Preparation 
100 mg of extract was weighed and dissolved in 70% methanol to get a 
concentration of 10mg/ml concentration this is then used for injection.  
 
Chromatographic Conditions 
Stationary Phase                      : Silica gel 60 F 254   
Mobile Phase                           : chloroform: methanol (9:1) 
Scanning Wavelength               : 404 nm  
Applied volume                       : 10µl 
Development mode                 : Ascending mode 
 
 
 
Inference  
HPTLC fingerprint of RH -1 shows four peaks at Rf values 0.25, 0.31, 0.41 & 
0.95.  The peak correspond to the Rf value 0.31 has maximum peak area of 7256.5. At 
this stage it is difficult to confirm the individual components present in the extract, but 
from SRM lab experience on phytochemical analysis, They suggest that the major peaks 
found in the fingerprint may be acidic glycosides / resins. Since, in the present 
chromatographic conditions, the above mentioned components will be eluted easy.  
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CHROMATOGRAPHIC CONDITION FOR HPTLC FINGER PRINT 
HPTLC WAS DONE AT SRI RAMACHANDRA UNIVERSITY. 
Sample Name   :  Chithiramoola Rasayanam  
Sample-ID                   : 108 
Stationary phase : Silica gel F 254 
    Mobile phase  : n-Hexane: Ethyl acetate:Formic acid 60:40:2.5 ml) 
Scanning wavelength :  254,298,489 nm 
Sample concentration :  20 mg/ml 
Injecting volume :  5, 10 µl  
Development mode :  ascending mode 
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BIO -CHEMICAL ANALYSIS OF CHITHIRAMOOLA RASAYANAM 
 The biochemical analysis of the Chithiramoola Rasayanam was carried out in the 
Biochemistry lab, National Institute Of Siddha. 
 
S.No EXPERIMENT OBSERVATION INFERENCE 
1. Appearance of sample Light Brown in colour.  
2. 
Solubility: 
a. A little(500mg) of the sample 
was shaken well with distilled water. 
b. A little(500mg) of the sample 
was shaken well with con. HCl/Con. 
H2So4 
Sparingly soluble 
 
 
Absence of 
Silicate 
3. 
Action of Heat: 
A small amount(500mg) of the sample 
was taken in a dry test tube and heated 
gartly at first and then strong. 
 
No white fumes 
evolved 
 
 
Absence of 
Carbonate 
 
4. 
Flame Test: 
A small amount(500mg) of the sample 
was made into a paste with con. HCl in 
a watch glass and introduced into non-
luminous part of the Bunsen flame. 
No Bluish green flame 
appeared. 
Absence of Copper 
5. 
Ash Test:    A filter paper was soaked 
into a mixture of sample and dil. cobalt 
nitrate solution and introduced into the 
Bunsen flame and ignited. 
Yellow colour flame 
appeared. 
Presence of 
sodium 
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Preparation of Extract: 
 5gm of Chithiramoola Rasayanam was weighed accurately and placed in a 250ml 
clean beaker and added with 50ml of distilled water. Then it was boiled well for about 10 
minutes. Then it was cooled and filtered in a 100ml volumetric flask and made up to 
100ml with distilled water. 
 
S.No EXPERIMENT OBSERVATION INFERENCE 
 I.Test For Acid Radicals   
1. 
Test For Sulphate: 
a. 2ml of the above prepared extract 
was taken in a test tube to this added 2ml 
of 4% dil ammonium oxalate solution 
b. 2ml of the above prepared extracts 
was added with 2ml of dil-HCl was added 
until the effervescence ceases off. Then 
2ml of dil.Barium chloride solution was 
added. 
Cloudy appearance 
present 
 
 
Absence 
of Sulphate 
 
 
 
2. 
Test For Chloride: 
2ml of the above prepared extract was 
added with dil. HCl till the effervescence 
ceases. Then 2ml of dil.silver nitrate 
solution was added. 
No cloudy 
appearance. 
Absence 
of Chloride 
3. 
Test For Phosphate: 
2ml of the extract was treated with 2ml of 
dil.ammonium molybdate solution and 
2ml of con.HNo3. 
Yellow appearance 
present 
Presence 
of Phosphate 
4 
. 
Test For Carbonate: 
2ml of the extract was treated with 2ml 
dil. Magnesium sulphate solution 
No Cloudy 
appearance. 
Absence 
of carbonate 
5. 
Test For Nitrate: 
1gm of the substance was heated with 
copper turning and concentrated H2So4 
and viewed the test tube vertically down. 
 
No Brown gas 
evolved. 
 
Absence 
of Nitrate 
6. 
Test For Sulphide: 
1gm of the substance was treated with 2ml 
of con. HCL 
No Rotten Egg 
Smelling gas. 
Absence 
of Sulphide 
7. 
Test For Fluoride & Oxalate: 
2ml of extract was added with 2ml of dil. 
Acetic acid and 2ml dil.calcium chloride 
solution and heated. 
No Cloudy 
appearance 
Absence 
of fluoride and 
oxalate 
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8. 
Test For Nitrite: 
3drops of the extract was placed on a filter 
paper, on that-2 drops of dil.acetic acid 
and 2 drops of dil.Benzidine solution was 
placed. 
No Characteristic 
changes 
Absence 
of Nitrite 
9. 
Test For Borate: 
2 Pinches(50mg) of the substance was 
made into paste by using dil.sulphuric 
acid and alcohol (95%) and introduced 
into the blue flame. 
No Bluish green 
colour flame. 
Absence 
of borate 
 II. Test For Basic Radicals   
1. 
Test For Lead: 
2ml of the extract was added with 2ml of 
dil.potassium iodine solution. 
No yellow 
Precipitate 
obtained. 
Absence of Lead 
2. 
Test For Copper: 
One pinch(50mg) of substance was made 
into paste with con. HClin a watch glass 
and introduced into the non-luminuous 
part of the flame. 
No Blue colour 
flame 
No Blue colour 
precipitate formed. 
 
Absence 
of copper 
 
 
3. 
Test For Aluminium: 
To the 2ml of extract, dil.sodium 
hydroxide was added in 5 drops to excess. 
Yellow colour 
appeared. 
Presence 
of aluminium 
4. 
Test For Iron: 
a. To the 2ml of extract,2ml of 
dil.ammonium solution was added. 
b. To the 2ml of extract 2ml  
thiocyanate solution and 2ml  of con 
HNo3 was added 
 
blood red colour 
appeared. 
 
 
 
Presence of Iron 
 
 
5. 
Test For Zinc: 
To 2ml of the extract, dil.sodium 
hydroxide solution was added in 5 drops 
to excess and dil.ammonium chloride was 
added. 
 
No White 
precipitate was  
formed 
 
Absence of Zinc 
6. 
Test For Calcium: 
2ml of the extract was added with 2ml of 
4% dil.ammonium oxalate solution 
No Cloudy 
appearance and 
white precipitate 
was obtained 
 
Absence 
of calcium 
7. 
Test For Magnesium: 
To 2ml of extract dil.sodium hydroxide 
solution was added in drops to excess. 
 
White precipitate 
was  obtained 
 
Absence 
of Magnesium 
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8. 
Test For Ammonium: 
To 2ml of extract 1 ml of Nessler's 
reagent and excess of dil.sodium 
hydroxide solution are added. 
 
No Brown colour 
appeared 
 
Absence 
of ammonium 
9. 
Test For Potassium: 
A pinch(25mg) of substance was treated 
of with 2ml of dil.sodium nitrite solution 
and then treated with 2ml of dil.cobalt 
nitrate in 30% dil.glacial acetic acid. 
 
No Yellowish 
precipitate was 
obtained. 
 
Absence 
of Potassium 
10. 
Test For Sodium: 
2 pinches(50mg) of the substance was 
made into paste by using HCl and 
introduced into the blue flame of Bunsen 
burner. 
yellow colour 
flame appeared 
Presence 
of sodium 
11. 
Test For Mercury: 
2ml of the extract was treated with 2ml of 
dil.sodium hydroxide solution. 
No yellow 
precipitate was 
obtained 
Absence 
of mercury 
12. 
Test For Arsenic: 
2ml of the extract was treated with 2ml of 
dil.sodium hydroxide solution. 
 
No brownwish red 
precipitate was 
obtained 
 
Absence 
of arsenic 
 III. Miscellaneous   
1. 
Test For Starch: 
2ml of extract was treated with weak 
dil.iodine solution 
 
No  blue colour 
developed 
 
Absence 
of starch 
2. 
Test For Reducing Sugar: 
5ml of Benedict's qualitative solution was 
taken in a test tube and allowed to boil for 
2 minutes and added 8 to 10 drops of the 
extract and again boil it for 2 minutes. The 
colour changes are noted. 
 
Brick red colour 
not developed 
 
Presence of  
reducing sugar 
3. 
Test For The Alkaloids: 
a) 2ml of the extract was treated with  2ml 
of dil.potassium iodide solution. 
b)  2ml of the extract was treated with  
2ml of dil.picric acid. 
c)  2ml of the extract was treated with 2ml 
of dil.phosphotungstic acid. 
 
. 
 
Yellow colour 
developed 
 
 
 
Presence 
of Alkaloid 
4. 
Test For Tannic Acid: 
2ml of extract was treated with 2ml of 
dil.ferric chloride solution 
No black 
precipitate was 
obtained 
Presence 
of Tannic acid 
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5. 
Test For Unsaturated Compound: 
To the 2ml of extract 2ml of dil.Potassium 
permanganate solution was added. 
 
Potassium 
permanganate was 
not decolourised 
 
Absence of 
unsaturated 
compound 
6. 
Test For Amino Acid: 
2 drops of the extract was placed on a 
filter paper and dried well. 20ml of  
Biurette reagent was added. 
 
violet colour 
developed 
 
Presence 
of amino acids 
7. 
Test For Type Of Compound: 
2ml of the extract was treated with 2 ml of 
dil.ferric chloride solution. 
No green colour 
developed 
 
 
No red colour 
developed 
 
 
 
No violet colour 
developed 
 
No blue colour 
developed 
Absence of 
oxyquinole 
pinephrine and 
pyro catechol 
Anti pyrine, 
Aliphatic amino 
acids and  
meconic acid are 
absent 
Apomorphine 
salicylate and 
Resorcinol are 
absent 
Morphine, 
Phenol cresol 
and hydro 
uinone are 
absent 
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TOXICITY STUDY 
ACUTE AND SUB ACUTE TOXICITY STUDY ON CHITHIRAMOOLA 
RASAYANAM IN RODENTS 
 
Animals:  
 Mice of either sex weighing 25-30g and rats weighing 210-240g were obtained 
from the animal house of Vels University. The animals were used with the approval of the 
Institute Animal Ethics Committee and obtained from Vels University, Chennai. They 
were fed with a balanced standard pellet diet and maintained under standard laboratory 
conditions, providing 24-280C temperature, standard light cycle (12 h light, 12 h dark) 
and water ad libitum. Animals were kept in cages with raised floors of wide mesh to 
prevent coprophagy. Animal welfare guidelines were observed during the maintenance 
period and experimentation. The rats were randomly assigned to control and different 
treatment groups, six animals per group. (Approval number: 
XIII/VELS/PCOL/32/2000/CPCSEA/IAEC/08.08.2012). The animals were acclimatized 
for one week under laboratory conditions.  
 
ACUTE TOXICITY STUDY-OECD 425 GUIDELINES 
 Acute oral toxicity test for the Chithiramoola Rasayanam was carried out as per 
OECD Guidelines 425. As with other sequential test designs, care was taken to ensure 
that animals are available in the appropriate size and age range for the entire study. The 
test substance is administered in a single dose by gavage using a stomach tube or a 
suitable intubation cannula. The fasted body weight of each animal is determined and the 
dose is calculated according to the body weight. After the substance has been 
administered, food was withheld for a further 2 hours in mice. The animals were observed 
continuously for the first 4 h and then each hour for the next 24 h and at 6 hourly intervals 
for the following 48 h after administering of the test drug, to observe any death or 
changes in general behaviour and other physiological activities. Single animals are dosed 
in sequence usually at 48 h intervals. However, the time interval between dosing is 
determined by the onset, duration, and severity of toxic signs. Treatment of an animal at 
the next dose was delayed until one is confident of survival of the previously dosed 
animal.  
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Observation of toxicity signs: General behavior, respiratory pattern, cardiovascular signs, 
motor activities, reflexes, change in skin and fur, mortality and the body weight changes 
were monitored daily. The time of onset, intensity, and duration of these signs, if any, 
were recorded.  
 
Stock solution and Acute toxicity study 
 Acute oral toxicity study was performed as per OECD-425 guidelines. Mice (n=6) 
of either sex selected by random sampling technique were used for acute toxicity study. 
The animals were kept fasting for overnight providing only water, after which the 
Chithiramoola Rasayanam in 2% CMC was administered orally at the different dose 
levels in up and down dosing schedule according to body weight by gastric intubation and 
observed for 14 days.  
 
SUB-ACUTE TOXICITY  
 In a 28-days sub acute toxicity study, twenty four rats of either sex were divided 
into four groups of 6 rats each. Groups of rats I, II and III were administered daily with 
the Chithiramoola Rasayanam (p.o.) for 28 days at a dose of 100, 250 and 500mg/kg 
respectively. The animals were then observed daily for gross behavioural changes and 
any other signs of sub-acute toxicity. The weight of each rat was recorded on day 0 and 
weekly throughout the course of the study, food and water consumption per rat was 
calculated. At the end of the 28 days they were fasted overnight, each animal was 
anaesthetized with diethylether, following which they were then dissected and blood 
samples were obtained by retro orbital puncture into heparinised tubes. The blood sample 
collected from each rat was centrifuged with 3000 X g at 4oC for 10 min to separate the 
serum and used for the biochemical assays.  
 
Hematological and blood biochemical analyses:  
At the end of the study, all animals were kept fasted for 16-18 h and then anesthetized 
with anesthetic ether on the 28th day. Blood samples for hematological and blood 
chemical analyses were taken from retro orbital vein. Heparinized blood samples were 
taken for determining complete blood count (white blood cell count, differential white 
blood cell count, platelet count, red blood cell count, and hemoglobin etc..) by 
semiautomated hematology analyzer. The serum from non-heparinized blood was 
carefully collected for blood chemistry and enzyme analysis (Glucose, creatinine, total 
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protein, albumin, total and direct bilirubins, serum glutamate-oxaloacetate transaminase 
(SGOT), serum glutamate pyruvate transaminase (SGPT), and alkaline phosphatase 
(ALP) etc..) were automatically determined using autoanalyzer. 
Necropsy:  
 All rats were sacrificed after the blood collection. The positions, shapes, sizes and 
colors of internal organs were evaluated. The Spleen, Testes, Pancreas, Lung, Liver, 
Brain, Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues were excised from all 
rats to visually detect gross lesions, and weighed to determine relative organs, weights 
and preserved in 10% neutral formalin for histopathological assessment. The tissues were 
embedded in paraffin, and then sectioned, stained with haematoxylin and eosin and were 
examined microscopically. 
 
Statistical analysis 
Values were represented as mean ± SEM. Data were analysed using one-way analysis of 
variance (ANOVA) and group means were compared using the Dunnet’s ‘t’ Test using 
GraphPad Instat-V3 software. P values < 0.05 were considered significant. 
 
RESULTS AND DISCUSSION 
 The acute toxicity study of the Chithiramoola Rasayanam indicated no changes in 
the behaviour and in the sensory nervous system responses in the animals. Also no 
adverse gastrointestinal effects were observed in the male and female mice used in the 
experiment. All the mice that received up to 5.0g/kg dose of the Chithiramoola 
Rasayanam survived beyond the 24 hours of observation. Hence the dose was fixed as 
100, 250 and 500mg/kg for further sub acute toxicity study.  
 During the sub-acute toxicity tests, the results obtained on the average daily water, 
food intake and periodical weight gain (P<0.01). The eating and drinking habit and 
behavior of all the animals used were normal in both vehicle-treated and Chithiramoola 
Rasayanam treated animals. The results revealed that essential organs such as the liver, 
kidney, spleen and testes were not adversely affected during the sub-acute administration. 
Acute and sub-acute oral administration of Chithiramoola Rasayanam did not cause any 
significant changes in gross behavioural effects in rodents.  
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 The changes in the SGPT, total protein and albumin concentrations following the 
administration of 0.25,0.5 g/kg of Chithiramoola Rasayanam was observed (P<0.01) and 
showed significant alterations in the serum HDL, LDL and Uric acid (P<0.01) 
concentration when compared to the control. On the other hand, there was a significant 
increase in the triglyceride concentration but statistically not significant. Significant 
alterations were observed in monocyte count. No other heamatological changes were 
identified. Macroscopically, the liver, spleen, lung, testis and the kidney showed no 
discolouration and the textures were consistent when compared with the control groups. 
Slightly significant reduction in weight was observed in the vital organs like Spleen, brain 
and kidney. Histopathological examination revealed that the spleens, livers, lung, testes 
and the kidneys of rats administered with Chithiramoola Rasayanam showed no 
differences relative to those of the control group at the two dose levels, though there was 
focal proximal tubular epithelial necrosis in the kidney at 5.0 g/kg. These results indicate 
that Chithiramoola Rasayanam at 0.5 g/kg body weight is not toxic to the liver, spleen 
and testes of rat but has a minor effect on the lungs and kidney. Thus, since there was no 
any significant changes in serum levels of glucose, triglycerides concentration following a 
28 days treatment of the Chithiramoola Rasayanam, it may indicate therefore, that it is not 
toxic to the animal.  
 In conclusion, the present results show that Chithiramoola Rasayanam possesses 
negligible toxicity as indicated in our rat model. No deaths or signs of toxicity were 
observed in the rats that received the Chithiramoola Rasayanam up to an oral acute dose 
of 5g/kg thus establishing its safety in use. 
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HISTOPATHOLOGY 
Chithiramoola Rasayanam(500mg) 
 
      Bone                                                                  Brain 
 
 
 
 
 
 
 
Heart                                                                                                   Intestine 
 
  
 
                                                      
 
                  
 
    
 
Kidney                                                                                                   Liver 
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     Lung                                                                                                               Spleen                                                                                                                             
                                                                          
          
 
 
 
 
 
            Ovary                                                                                                   Testis                                                                                    
                                                                         
           
  
 
 
 
 
 
Pancreas                                                                                  Stomach                                                                                                           
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PHARMACOLOGICAL STUDY 
ACUTE ANTI INFLAMMATORY ACTIVITY OF CHITHIRAMOOLA 
RASAYANAM IN RATS 
 
MATERIALS AND METHODS 
Animals                                                                                                                                                        
 Male albino Wistar rats (190-210 g) were obtained from the animal house of the 
School of Pharmaceutical Sciences, Vels University, Chennai. They were kept at standard 
environmental conditions (12/12-h light/dark cycle) and were allowed free access to food 
and water. Before each test, the animals were fasted for 24 h with free access to water. 
The rats were randomly divided into test and control groups, each group consisted of age 
and weight matched rats (n =6). The experimental protocol was approved by the animal 
ethical committee of Vels University. 
(Approval number:XIII/VELS/PCOL/32/2000/CPCSEA/IAEC/08.08.2012)      
               
ACUTE ANTI-INFLAMMATORY EVALUATION 
Formalin induced method 
 Male Albino Wistar rats, 190–210 g, were kept in Polypropylene cages with free 
access to food and water. Testing took place in the middle of the light period of a 12:12-h 
light:dark cycle. The Chithiramoola Rasayanam was suspended in vehicle (2% carboxy 
methyl cellulose (CMC) in saline) and administered orally at a dose of 100, 250, 500 
mg/kg and 45mg/kg for Diclofenac sodium. The rats were divided in to five groups (n=6) 
and the first group treated with saline (5ml/kg), second group treated with Diclofenac 
sodium (45mg/kg) and third, fourth and fifth group treated with Chithiramoola 
Rasayanam 100, 250 and 500mg/kg respectively through orally. Oedema was produced 
by subplantar injection of formalin in the right hindpaw of each rat one hour after the 
administration of corresponding drugs. The paw volume was measured at 1,2,3 and 4 hr 
after the injection of formalin using the plethysmometer. Mean increase in the paw 
volume of oedema was measured. 
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Statistical analysis 
 The data are expressed as mean±SEM. Student t-test followed by Dunnet ‘t’ test 
was used to determine significant differences between groups. p-values less than 0.05 
were considered as indicative of significance. 
RESULT AND DISCUSSION 
 In Indian system of medicine, certain drugs are claimed to provide relief of 
inflammation. The claimed therapeutic reputation has to be verified in a scientific 
manner. Inflammation is a complex process and ROS play an important role in the 
pathogenesis of inflammatory diseases. The main action of anti-inflammatory agents in 
the inhibition of cyclooxygenase enzyme, which are responsible for conversion of 
arachidonic acid to prostaglandin (PG). The extracellular activity of these enzymes is said 
to be related to acute and chronic inflammation. NSAID’S act either by inhibiting these 
lysosomal enzymes (Cyclooxygenase). In the Present Study, the result suggests that the 
test drug Chitramoola Rasayanam becomes significant within two hour, during the 
phagocytic phase of formalin-induced inflammation. Inflammation is a normal protective 
response to tissue injury caused by physical trauma, noxious chemicals or microbiologic 
agents. Inflammation is body’s response to inactivate or destroy the invading organisms, 
remove irritants and set stage for tissue repair. Inflammation is triggered by the release of 
chemical mediators from the injured tissues and migrating cells. The specific chemical 
mediators vary with the type of inflammatory process and include amines such as 
histamine, serotonin, lipids such as prostaglandins and small peptides such as Kinins. 
Prostaglandins (PGs) play significant role in different phases of inflammatory reactions. 
PGs elicit pain by direct stimulation of sensory nerve endings and also sensitize sensory 
nerve endings to other pain provoking stimuli. Moreover, PGs especially PGE1 was 
reported to act on cell membrane during inflammatory conditions leading to changes in 
lipoprotein structure of cell membrane. This causes destabilization of cell membrane 
furthering to degenerative cellular changes. 
 An important feature of the formalin test in rodents is that the animal show two 
phases of nociceptive behavior which possibly involves two distinctly different stimuli. 
The first phase starts immediately after injection of the formalin and lasts for 3-5 min. 
Evidences show that effect on the opioid receptors is one of the main ways involved in 
exertion of antinociceptive effects in this phase. The most widely used primary test to 
screen new anti-inflammatory agents measures the ability of a compound to reduce local 
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edema induced in the rat paw by injection of an irritant agent. This edema depends on the 
participation of kinins and polymorphonuclear leukocytes with their proinflammatory 
factors including prostaglandins.  
 The development of edema in the paw of the rat after the injection of irritants has 
been described as a biphasic event. The initial phase, observed around 1 h, is attributed to 
the release of histamine and serotonin; the second, accelerating phase of swelling is due 
to the release of prostaglandin-like substances. It has been reported that the second phase 
of edema is sensitive to both clinically useful steroidal and nonsteroidal anti-
inflammatory agents.  
 The specific chemical mediators vary with the type of inflammatory process and 
include amines such as histamine, serotonin, lipids such as prostaglandins and small 
peptides such as Kinins.  Formalin-induced pain is caused primarily by peripheral tissue 
inflammation. Acute inflammation may last for relatively shorter duration, ranging from 
few minutes to few days. Exudation of fluid and plasma proteins, emigration of 
leukocytes, and predominantly neutrophils, are characteristic changes. The Chithiramoola 
Rasayanam as well as diclofenac showed Anti-phleogestic activity. It can be assumed that 
the test drug Chithiramoola Rasayanam exert its anti-inflammatory effect through 
mechanism similar NSAIDs. Formalin-induced paw oedema is one of the most suitable 
test procedures to screen chronic anti-inflammatory agents, as it closely resembled human 
arthritis. The nociceptive effect of formalin is also biphasic; an early neurogenic 
component followed by a later tissue-mediated response. The result suggests the 
usefulness of Chithiramoola Rasayanam in the treatment of inflammation associated 
diseases like arthritis. The pattern of anti-inflammatory activity exhibited by this 
Chithiramoola Rasayanam was similar to that of diclofenac which suggests that the 
activity may be mediated by cyclooxygenase I and II inhibition. This anti-inflammatory 
activity was found to be statistically significant (P<0.01) at all the concentration used 
after 120minutes of drug treatment. 
 
 
 
 
 
 
 
88 
 
ANALGESIC ACTIVITY OF CHITHIRAMOOLA RASAYANAM IN MICE 
 
 Mice of either sex  with an intial  weight  21-41g of mice were obtained from the 
animal house of the School of Pharmaceutical Sciences, Vels University, Chennai. They 
were kept at standard environmental conditions (12/12-h light/dark cycle) and were 
allowed free access to food and water. Before each test, the animals were fasted for 24 h 
with free access to water. The rats were randomly divided into test and control groups, 
each group consisted of age and weight matched rats (n =6). The experimental protocol 
was approved by the animal ethical committee of Vels University. 
(Approval number: XIII/VELS/PCOL/32/2000/CPCSEA/IAEC/08.08.2012) 
 
  PROCEDURE 
 The present study was undertaken to study the analgesic activity of Chithiramoola 
Rasayanam- A Siddha Drug and was assessed by the Eddy’s hot plate method in mice. 
The following procedure has been used in this study. Groups of 6 mice of either sex with 
an initial weight of 22 to 41 g were used. The hot plate, which is commercially available, 
consists of a electrically heated surface. The temperature is controlled for 55° to 56 °C. 
The animals are placed on the hot plate and the time until either licking or jumping occurs 
is recorded by a stop-watch. The latency is recorded before and after 15, 30, 45, 60 and 
90 min following oral or intra peritoneal administration of the standard or the 
Chithiramoola Rasayanam. 
 
RESULTS AND DISCUSSION 
 The prolongation of the latency times comparing the values before and after 
administration of the Chithiramoola Rasayanam with the experimental groups used for 
statistical comparison using the One way-ANOVA followed by Dunnet test. 
Alternatively, the values which exceed the value before administration for 50% or 100% 
can be regarded as positive. Doses of pentazocine hydrochloride (5mg/kg) and 100, 250 
and 500mg/kg p.o.. Chithiramoola Rasayanam was considered for treatment. Analgesic 
effect lasted for a period of 90min was found to possess significant (P<0.01) analgesic 
activity at 250 and 500mg/kg dose levels. There was increase in % of reaction time by 
dose dependant manner.   
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DISEASE ASPECT 
SIDDHA ASPECT 
NiynehŒ6 
ntWbga®fŸ : 
 KU¡fšnehŒ, F¤jš nehŒ, FlštÈ vd¥ gy bga®fS©L. 
ïašò : 
 Ny« v‹D« fUÉahš F¤J§fhš c©lhF« tÈia bah¤j 
nehŒ¡F Niy nehŒ vd¥ bgauhÆ‰W.  Ny« v‹w fUÉahš 
F¤J§fhY©lhF« tÈiabah¤j nehia, ïiu¥ig, Flš g¡f« 
(Éyh), _£LfŸ ït‰¿Y©lhF« F¤jš nehah«. 
nehŒtU« tÊ : 
 “rh®thd NiytU khW nfshŒ- 
  j¡fáiw¥ g£oU¡Fª ÔikahY« 
 M®thd tw¢RLnrh wUªj yhY« 
  mwînk rÈ¥ghY nkhl yhYª 
 jh®thd rigÄFªj r©il ahY« 
  jifahd Jt®¥bghá¥ò òif¤j yhY« 
 nt®thd nkhf¤â‹ òz®¢á ahY« 
  ÄFªjgá íWjÈdh‰ Niy ahnk” 
 “Mbk‹w t‹d¤J¡ »Wâ g©Â 
  aâfgu njáfis ao¤j ng®¡F§ 
 fhbk‹w f‰òila k§if khiu¡ 
  fUâna kd¤JË¢ á¤j ng®¡F« 
 thbk‹w thœku¤ij bt£o ndh®¡F« 
  tÊk¿¤J bghUŸg¿¤j kânf l®¡F« 
 Vbk‹w v¢áwid¡ ft®ªj ng®¡F«  
  ïf¤âny nehbtŒâ¢ Niy ahnk” 
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bghUŸ : 
 áiw¥g£oU¤jš, Äf¢ Nlhd g©l§fis c©zš, kd¢rÈ¥ò 
bfhŸsš, Xlš, j‹ t‹ik¡F ÄFªj r©ilÆlš, Jt®¥ò¥ 
bghU£fis mo¡fo¡F bfhŸsš, òif ão¤jš, msÉ‰F ÉŠá¥ 
bg©fyÉ brŒjš M»at‰whš Niy nehŒ c©lhF«. 
 ViHf£F czÉlhkš mt®fis mo¤njh£oatU¡F«, ÄFªj 
bg©zhirahš f‰òila k§ifaiu ÉU«ãat®¡F«, ga‹ju¡ Toa 
ku§fis bt£o åœ¤âatU¡F«, bghUË¢irahš tÊg¿¡F« 
m¿ÉÈfS¡F«, j‹ v¢áiy¤ bjÇahkš ãw®¡F bfhL¥gt®¡F« 
ïªnehŒ c©lhF« vd ü‰fŸ TW«. 
K‰F¿fŸ : 
 clš FË®ªjh‰ ngh‰nwh‹¿, _¡»š Ú® ghŒjš, f© át¤jš, r‰W 
Ru« fhŒjš, clš td¥ò¡ Fiwjš v‹D« K‰ F¿fisí« fh£o, g¡f«, 
iffhš, ó£LfŸ ïitfËš F¤jiy c©lh¡F«.  
Niy F¿Fz« : 
· nehŒ ãw¡F« ïl§fËš r‰W å§»¢ átªJ, F¤jiy c©lh¡F« 
· F¤jÈ‹ t‹iknf‰g, ÄFRu«, thªâ, ka¡f«, jiynehŒ, f© 
át¤jš, fhJnfshik, m¿î F‹wš, thŒ ãj‰wš V‰gL«. 
· nehÆ‹ tÈ jh§f KoahJ clš Éa®¤jš, ifí« fhY« ášÈ£L 
nghjš, _¡F EÅ Ú©L nghjš, f© gŠriljš V‰gL«. 
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F‰w KjÈa ntWghLfŸ : 
 “beLthj rh®tJÄ‹¿¢ Niy thuhJ” 
 tË¡F‰w« ÄFªJ clÈ‰w§» mjdhš fhšfËš (thífËš) nkš 
neh¡F¡ fhš, Ñœneh¡F¡ fhšfË‹ t‹ikÄFªJ nehia¥ ãw¥ã¡F«. 
 nehbaGªj fhiy ïU F‰w§fSŸ x‹nwD«, ïu©nlD«, 
TLkhjÈ‹, nehŒ t‹ikí« bgUF«. 
 clÈ‹ cW¥òfËš F¤jš, Filjš, tÈ¤jš, òu£lš v‹D§ 
F¿fisí« áWÚ®, vU ït‰iw btËnaw¢ brŒahJ f£Ljyh»a 
braiyí« c©lh¡F«. 
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OSTEOARTHRITIS34 
 
 Osteoarthritis  is also erroneously called degenerative joint disease, represent 
diarthroidal (movable, synovial-lined ) joint. Osteoarthritis (OA)  is characterized  by 
focal loss of articular cartilage and proliferation and remodelling  of bones around the 
joint to form osteophyte . Inflammation can be a feature of osteoarthritis. 
 Osteoarthritis  represents an imbalance in destruction and synthetic process of the 
cartilage  lead to the erosion, decreased concentration and viscosity of the synovial fluid 
,decreased lubricating and cushioning properties . There is also an underlying 
inflammation of the synovium as well as damage in the subchondral bone. 
 
EPIDEMIOLOGY: 
· Osteoarthritis (OA) affects 10-15% of world population.30      
· About  5.7% of population of India has Osteoarthritis (OA). 31    
· In general prevalence of osteoarthritis increases with age   
· 80% of people affected by 40 years. More than 50% have bilateral  osteoarthritis  
· Women have great tendency than men.32 
· Genetic tendency in knee osteoarthritis is twice as  osteoarthritis hip  
· Knee osteoarthritis is the leading cause of chronic disability in developed 
countries among elders, some people are unable to walk independly from bed to 
bathroom because of knee osteoarthritis.  
 
RISK FACTORS21: 
  Age   : Repetitive stress, e.g. vocations, obesity 
  Female  : obesity 
  Genetic factors : Prior inflammatory joint disease 
  Major joint trauma : Metabolic / Endocrine disorder 
TYPES: 
 Primary / Idiopathic osteoarthritis 
 Secondary osteoarthritis   
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Primary /idiopathic osteoarthritis.  
Localised Osteoarthritis : 
   Hands (Herbenden's node,bouchard,s node) 
   Feet (Hallux valgus,Hallux rigidus) 
Knee: 
 Medial Compartment knee osteoarthritis 
 Lateral Compartment knee osteoarthritis 
 Patellofemoral Compartment knee osteoarthritis 
Hip: 
 Eccentric (superior) 
 Concentric (axial, medial) 
 Diffuse (coxae senilis) 
Secondary  Osteoarthritis. 
 Trauma. e.g. sports   
 Congenital or developmental:e.g. valgus, varus deformity. 
 Metabolic, e.g. Wilsons disease 
 Endocrine, e.g. obesity, diabetes mellitus. 
 
CLINICAL FEATURES: 
 Pain 
 Swelling 
 Stiffness 
 Restricted movements 
 Crepitus 
 Tenderness 
 
COMPLICATIONS: 
 Joint deformity 
 Subluxation 
 Ankylosis  
 Intra articular loose bodies  
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STUDY DESIGN : 
The study was conducted on patients with Soolai (Osteoarthritis) patients satisfying the 
inclusion criteria.  
 Study place :  NIS (OPD,IPD) 
 Period          : 12 months 
 Sample size : 20 patients (both sex) 
 Weight         :  35-85 kg 
 Dose             :  5gm bid 
 Duration      : 40 days 
 
SUBJECT SELECTION: 
Inclusion Criteria:   
             1.    Age       :35-65 years 
             2.   Sex         :both male and female 
             3.  Weight   :35-85 kg 
             4.  Patient, having symptoms of 
    One or both  knee joints pain 
    One or both knee joint swelling 
    Stiffness 
    Crepitus 
    Restricted movements of knee joint  
      Any of the 2 clinical symptoms. 
            5.  Patienst who are willing to provide blood for lab investigation. 
            6.  patients who are willing to undergo Radiological investigation. 
           7.  Patients willing to sign the informed consent stating that he/she will 
conscientiously stick to the treatment during 40 days but can opt out of the trial of his/her 
own conscious discretion. 
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Exclusion criteria:         
                        Rheumatoid arthritis 
      Gouty arthritis 
                 Tuberculosis 
      Viral fever 
      History of trauma 
       Any other serious illness 
Withdrawal criteria: 
      1. Development of any adverse reaction  
      2. Occurrence of any other serious illness 
      3. Non co-operation of the patient 
TESTS AND ASSESMENTS 
C. Clinical assessment  
Siddha assessment 
D. Laboratory Investigations 
  Routine investigations 
 Clinical assessment: 
 Patient, having symptoms of 
    One or both  knee joints pain 
    One or both knee joint swelling 
    Stiffness 
    Crepitus 
    Restricted movements of knee joint  
      Any of the 2 clinical symptoms. 
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PAIN SCALE 
 
  Grade   0    : No Pain 
                Grade  1 -3 :  Mild pain 
                 Grade  4-6 :  Moderate pain 
                         Grade  7-10 :  Severe pain     
 
2. RESTRICTED MOVEMENT ASSESSMENT SCALE:                
Gradation of movements: 
Grade 1  - Fit for all activities, do their work without support. 
Grade II - Mild pain present in knee joint, mild restricted movements. 
Grade II - Pain present in knee joint, moderate restriction of movements. 
Grade IV - Severe pain, bed ridden. 
(Reference: Clinical manual for nursing practice (National Institute of Health Warren Grant 
Magnuson Clinical Centre) 
            5.  Patient who are willing to provide blood for lab investigation. 
            6.  patient who are willing to undergo Radiological investigation. 
           7.  Patient willing to sign the informed consent stating that he/she will 
conscientiously stick to the treatment during 40 days but can opt out of the trial of his/her 
own conscious discretion. 
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INVESTIGATION/ASSESSMENT: 
SIDDHA PARAMETERS: 
   Enn vagai thervu: 
1.Naa 
2.Niram 
3.Mozhi 
4.Vizhi 
5.Sparisam 
6.Naadi 
7.Malam 
8.Moothiram 
§ Neerkuri 
§ Neikuri 
ROUTINE INVESTIGATION 
Blood  
Hb (gm/dl )                                                                            
Total WBC Count( Cells/cumm)      
DC-  Polymorphs (%)                        
Lymphocytes (%) 
Eosinophils (%)  
Monocytes (%) 
Basophils (%) 
Total RBC count (Million cells / cu.mm)  
ESR (mm/hr) 
Blood glucose( mg/dl):    ( Fasting) 
( Post – prandial) 
Blood urea 
Serum creatinine 
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Liver function test: 
SGOT 
SGPT 
Serum total bilirubin 
Serum bilirubin (direct) 
Serum bilirubin(indirect) 
Serum alkaline phosphatase 
Serum total protein 
Serum albumin 
Serum globulin 
Serum calcium 
Serum phosphorus 
Serum uric acid 
Lipid Profile 
Serum cholesterol(mg/dl) 
 HDL cholesterol(mg/dl) 
 LDL cholesterol(mg/dl) 
VLDL cholesterol(mg/dl) 
Serum triglycerides  (mg/dl)   
 
X-RAY: Knee joint 
VDRL: 
Urine examination: 
 Albumin 
 Sugar (fasting  and post prandial) 
 Deposits 
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Specific investigation: 
 ASO Titre 
 RA Factor 
 CRP  
X-RAY 
 
STUDY ENROLLMENT:   
· In this pilot study, patients reporting at the OPD with the clinical symptoms of pain in 
one or both knee joints, swelling, crepitus, restricted movements, stiffness will  be 
examined clinically for enrolling in the study based on the inclusion and exclusion 
criteria.  
· The patients who are to be enrolled would be informed (Form IV C) about the study, 
trial drug, possible outcomes and the objectives of the study in the language and terms 
understandable to them. 
· After ascertaining the patient’s  willingness, informed consent would be obtained in 
writing from them in the consent form (Form IV-A). 
· All these patients will be given unique registration card in which patients’ 
Registration number of the study, Address, Phone number and Doctors phone number 
etc. will be given, so as to report  easily should any complications arise. 
· Complete clinical history, complaints and duration, examination findings-- all would 
be recorded symptom in the prescribed Proforma in the history and clinical 
assessment forms separately. Screening Form- I will be filled up; Form I-A,  Form –II 
and Form –III will be used for recording the patients’ history, clinical  examination of 
symptoms and  signs and laboratory investigations respectively. 
· Patients would be advised to take the trial drug and appropriate dietary advice (Form 
IV-D) would be given according to the patient's perfect understanding. 
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CONDUCT OF THE STUDY: 
· Osteoarthritis patient who satisfying the inclusion criteria will be admitted to the trial. 
· Patient informed consent will be obtained 
· For OP patients ,they should visit the hospital once in 7  days.  At each clinical visit 
clinical assessment is done and prognosis is noted.  
· For IP patients clinical assessment is daily and prognosis is noted 
· Laboratory investigations  are done  before the trial started and at end of the trial  for 
both OP & IP patients   .  
· For IP patients, who is not in a situation to stay in the hospital for a long time is 
advised to attend the OPD for the continuation of the treatment. After the end of the 
treatment also, the patient is advised to visit the OPD  for another 2months for follow-
up. If any trial patient who fails to collect the trial drug on the prescribed day but 
wants to continue in the trial from the next day or two, he/ she will be allowed, but 
defaulters of one week and more will not be allowed to continue and be withdrawn 
from the study with fresh case being included. 
 
DATA MANAGEMENT 
· After enrolling the patient in the study, a separate file for each patient will be opened 
and all forms will be filed in the file. Study No. and Patient No. will be entered on the 
top of file for easy identification. Whenever study patient visits OPD during the study 
period, the respective patient file will be taken and necessary recordings will be made 
at the assessment form or other suitable form. 
· The screening forms will be filed separately. 
 
· The Data recordings will be monitored for completion by HOD and adverse reactions 
by Pharmacovigilance department of NIS . All forms will be further scrutinized in 
presence of Investigators by Sr. Research Officer (Statistics) for logical errors and 
incompleteness of data to avoid any bias. No modification in the results is permitted 
for unbiased reports. 
 
OUTCOME: 
 Primary outcome is mainly assessed by  
o Reduction of clinical symptoms. 
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DISCUSSION 
 
 The principle aim of this study was to assess the pre-clinical safety and efficacy 
and to evaluate the therapeutic efficacy of the drug Chithiramoola Rasayanam in the 
management of Soolai. 
 As per Siddha text, in Soolai Vathaa  humors were deranged. Vatha thathu is 
responsible for the functioning of the Udal thathukal uniformly. Hence derangement of 
the Vatha kutram leads to impairment in Udal thathukal and in turn produces symptoms 
like tiredness, body ache, difficult to flexion and extention of joint, pain in all  joint ext. 
The literary evidence from the text Pulipani Vaithiyam  500 strongly supports the Anti-
inflammatory activity and Analgesic activity.The trial drug Chithiramoola Rasayanam 
was effective in the management of Soolai. 
 
Biochemical analysis: 
Biochemical analysis of the drug Chithiramoola Rasayanam  reveals the presence of 
sodium, phosphate, iron, tannic acid, Aluminium, phosphate and alkaloids. 
  Sodium25: 
 Important for acid-base balance. 
50% of body Sodium present  in  bone.* 
 Required for normal muscle irritability and cell permeability. 
 Sodium deficiency causes muscle cramps.  
Sodium reduces prostaglandin synthesis.  
Iron: 
 Iron prevents lipid peroxidation and protect the cell against the free radicals 
including superoxide. 
Peroxidase, the lysosomal enzyme, is required for electron transport chain and 
oxidative phagocytosis and killing of bacteria by neutrophils. 
 It is a component of heam which is required for the formation of hemoglobin . 
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Phosphate:  
 It is essential for the development of bones and teeth.*   
Toxicological studies:  
The acute toxicity study of the Chithiramoola Rasayanam indicated no changes in the 
behaviour and in the sensory nervous system responses in the animals. Also no adverse 
gastrointestinal effects were observed in the male and female mice used in the 
experiment. All the mice that received up to 5.0g/kg dose of the Chithiramoola 
Rasayanam survived beyond the 24 hours of observation 
  Toxicological study results indicate that Chithiramoola Rasayanam at0.25, 0.5 
g/kg body weight is not toxic to the liver, spleen and testes of rat but has a minor effect on 
the lungs and kidney. Thus, since there was no any significant changes in serum levels of 
glucose, triglycerides concentration following a 28 days treatment of the Chithiramoola 
Rasayanam, it may indicate therefore, that it is not toxic to the animal.  
 In conclusion, the present results show that Chithiramoola Rasayanam possesses 
negligible toxicity as indicated in our rat model. No deaths or signs of toxicity were 
observed in the rats that received the Chithiramoola Rasayanam up to an oral acute dose 
of 5g/kg thus establishing its safety in use. 
Pharmacological  Studies 
 Pharmacological  Studies suggests that the test drug Chithiramoola Rasayanam 
becomes significant within two hour, during the phagocytic phase of formalin-induced 
inflammation. The Chithiramoola Rasayanam as well as diclofenac showed Anti-
phleogestic activity. The pattern of Anti-inflammatory activity exhibited by this 
Chithiramoola Rasayanam was similar to that of diclofenac which suggests that the 
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activity may be mediated by cyclooxygenase I and II inhibition. This anti-inflammatory 
activity was found to be statistically significant (P<0.01) at all the concentration used 
after 120minutes of drug treatment. 
Clinical observation: 
 From the clinical study 95% of patients relieved from pain,89% of patients 
relieved from swelling, 71% of patients relieved from stiffness ,50% of patients relieved 
from crepitus, 85% of patients relieved from restricted movements and no adverse effects 
were observed during trial period. 
Bio-statistics: 
              Statistically, the paired ‘t’ test shows statistical significance for the symptoms 
before and after the treatment.(p<0.0001). 
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SUMMARY 
 
The literary evidence strongly supports the Anti-inflammatory activity of 
Chithiramoola Rasayanam. 
The drug Chithiramoola Rasayanam has been selected for this study to evaluate its  
efficacy on the Anti-inflammatory activity and Analgesic activity in the management of 
Soolai. 
Biochemical analysis of the drug Chithiramoola Rasayanam  reveals the presence 
of sodium, phosphate , iron, tannic acid and alkaloids. 
In the toxicological studies, the drug does not exhibit any mortality up to the dose 
of 5gm/kg ( p.o.) 
In the pharmacological studies the drug Chithiramoola Rasayanam exhibits 
significant Anti-inflammatory and Analgesic activity against low and higher doses.  
From the clinical study 95% of patients relieved from pain, 89% of patients 
relieved from swelling, 71% of patients relieved from stiffness , 50% of patients relieved 
from crepitus , 85% of patients relieved from restricted movements and no adverse effects 
were observed during trial period. 
 From the statistical analysis-paired ‘t’ test, the drug Chithiramoola  Rasayanam  is 
statistically significant. 
Statistically, the paired ‘t’ test shows statistical significance for  symptoms before 
and after the treatment.(p<0.0001) 
 The drug Chithiramoola Rasayanam has 
§ Anti-inflammatory and Analgesic Activity. 
§ No reported side effects 
§ No undoing effects 
§ Encouraging clinical results.  
From the clinical and statistical analysis it is proved that the drug Chithiramoola 
Rasayanam  is statistically significant on activity in the management of Soolai .  
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CONCLUSION 
 
Ø The literature and research journal review of the herbo drug  shows that it has 
Anti-inflammatory  activity. 
Ø The safety studies (acute toxicity and sub-oral toxicity) studies conducted revealed 
that the trial drug Chithiramoola  Rasayanam  is safe. There were no abnormalities 
found in blood investigation and histo-pathological examination. Hence it can be 
reasonably assumed that the drug is safe for human use. 
Ø The pharmacological study conducted in animal model shows significant Anti-
inflammatory  activity. 
Clinical study revealed the therapeutic efficacy of the trial drug by relieved from 
pain, patients relieved from swelling, relieved from stiffness, 85% of patients relieved 
from restricted movements and no adverse effects were observed during trial period. 
Ø  There were no adverse reactions complained during the clinical trial. 
Hence, the drug Chithiramoola  Rasayanam  can be used in the management of Soolai. 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLES FOR TRAIL DRUG-1 PALAGARAI PARPAM 
QUALITATIVE ANALYSIS: 
.S.NO PARAMETERS RESULTS 
1. Phosphate  Absent 
2. Sulphate Absent 
3. Magnesium Present 
4. Iron Present 
5 Aminoacids Present 
6. Starch Absent 
7. Flavonoids Absent 
8. Proteins Absent 
9. Tannic acid Absent 
10. Glycosides Absent 
  
Trail Drug 1Table -1 
                                                                                                                                                                                           
PHYSICAL PROPERTIES 
             
 
  
  
  
  
  
  
  
   
      
Trail Drug 1 Table -2 
 
S.NO 
 
                 Characteristic test 
 
     Results 
 
1. 
 
pH 
 
9.79 
 
2. 
 
Ash Value 
 
0.03 
 
3. 
 
Water soluble ash 
 
0.06 
 
4. 
 
Acid insoluble ash 
 
0.43 
   Preliminary Acid, Basic Radicals Screening Of Palagarai Parpam (PP) 
S.No. Constituents   PP 
1. Calcium + 
2. Iron (Ferric) + 
3. Iron (Ferrous) + 
4. Chloride + 
5. Phosphate _ 
6. Potassium _ 
7. Sodium + 
8. Sulphate _ 
             
Trail Drug 1Table -3 
 
 
METAL CONTENT: 
SAMPLE 
NAME 
 
Fe (ppm) 
 
Zn (ppm) 
 
K (ppm) 
 
Na (ppm) 
 
Ca (ppm) 
 
Mg (ppm) 
PALAGARAI 
PARPAM 
 
ND 
 
0.055 
 
_ 
 
_ 
 
0.021 
 
0.35 
   
       Trail Drug 1Table -4 
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Trial Drug 1 Chart 3 
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TRAIL  DRUG 1 
CLINICAL ASSESMENT 
AGE  DISTRIBUTION 
 
   AGE NO OF PATIENTS PERCENTAGE 
20-30Yrs 5 25 
30-40 yrs 6 30 
40-50 yrs 5 25 
50-60yrs 4 20 
  
AGE  DISTRIBUTION 
 
Nopt- Number of   Patients 
 
    
5
6
5
4
25
30
25
20
0
5
10
15
20
25
30
35
20-30YRS 30-40YRS 40-50YRS 50-60YRS
NOPT
%
 GENDER  DISTRIBUTION 
 
S.NO GENDER NO.OF PATIENTS PERCENTAGE 
1. FEMALE 2 10% 
2. MALE 18 90% 
 
 
GENDER  DISTRIBUTION 
 
 
 
 
 
 
 
 
 
90%
10%
GENDER
MALE
FEMALE
IMPROVEMENT  SHOWING SIGNS AND SYMPTOMS BEFORE AND AFTER 
TREATMENT OF KALLERAI NOI. 
 
 
IMPROVEMENT  SHOWING SIGNS AND SYMPTOMS BEFORE AND AFTER 
TREATMENT OF KALLERAI NOI. 
 
 
 
BT- BEFORE TREATME          
AT- AFTER TREATMENT        
AT - AFTER TREATMENT NO IMPROVEMENT 
100%
55%
85% 80% 80%
65%
25%
0
29% 31%
37.50%
46%
75%
100%
71% 69% 63.50%
54%
0%
20%
40%
60%
80%
100%
120%
UP. ABD. 
PAIN
VOMITING NAUSEA ANOREXIA MALAISE JAUNDICE
SYMPTOMS
BT
ATNI
ATI
SYMPTOMS        NO. OF PATIENTS  WITH SYMPTOMS 
   BT       AFTER   TREATMENT IMPROVEMENT 
PERCENTAGE 
NO 
IMPROVEMENT 
IMPROVEMENT 
UPPER 
ABDOMEN 
PAIN 
20 (100%) 5(25%) 15 (75%) 75% 
VOMITING 11(55%) 0 11 (100%) 100% 
NAUSEA 17(85%) 5(29%) 12 (71%) 71% 
ANOREXIA 16(80%) 5(31%) 11  (69%) 69% 
MALAISE 16(80%) 6(37.5%) 10(62.5%) 63.5% 
JAUNDICE 13(65%) 6(46%) 7(54%) 54% 
STATISTICAL ANALYSIS: 
All collected data were entered into MS Excel software using different columns as 
variables and rows as patients. SPSS software was used to perform statistical analysis. 
Basic descriptive statistics include frequency distributions and cross-tabulations were 
performed. The quantity variables were expressed as Mean ± Standard Deviation and 
qualitative data as percentage. A probability value of <0.05 was considered to indicate as 
statistical significance. Paired ‘t’ test was performed for determining the significance 
between before and after treatmen 
DRUG 1 
KALLERAL NOI 
Trail Drug 1 Table 13 
Paired t test for Symptoms before and after treatment: 
Variable Obs Mean Std.dev t.value P value 
Before 
symptoms 
20 
 
4.80 
 
0.894 
 
-10.031 P<0.0001 
After 
symptoms 
20 1.35 1.894 
 
For   symptom of mean± standard deviation  before treatment is 4.80 ± 0.894 and 
after treatment is 1.35 ± 1.894 which is statistically significant(p<0.0005). 
 
Trail Drug  1 Table 14 
Paired t test for total bilirubil before and after treatment: 
Total 
bilirubin 
Obs Mean Std.dev t.value P value 
Before 
symptoms 
20 
 
.2041 1.884 
 
2.871 P<0.01  
After 
symptoms 
20 1.245 .8678 
 
For   Total bilirubin of mean± standard deviation  before treatment is .2041and 
after treatment is 1.245which is statistically significan t ( p<0.01) .Paired t test for before 
and after treatment: 
 
Trail Drug 1 Table 15 
 
Paired t test for SGOT,SGPT before and after treatment: 
 
Variable Obs              Mean         Std.dev            t.value          P value 
SGOT SGPT SGOT SGPT SGOT SGPT SGOT SGPT 
Before 
symptoms 
20 
 
48.80 43.80 43.85 29.17 2.433 2.170 P<0.025 P<0.049 
After 
symptoms 
20 26.12 31.40 15.08 14.255 
 
For SGOT  of mean± standard deviation  before treatment is 48.80± 43.80 and 
after treatment is 26.12 ± 31.40 which is statistically significant(p<0.025).  
For SGPT of mean± standard deviation  before treatment is 43.80 ± 29.17 and 
after treatment is 31.40 ± 14.255 which is statistically significant(p<0.049). 
 
 
 
 
 
IMPROVEMENT IN  PROGNOSIS OF SYMPTOMS OF KALLERAL NOI 
 
 
 
 
 
S.NO 
 
OP/IP 
 
AGE 
 
SEX 
 
MALAISE 
ANOREXIA 
 
NAUSEA VOMITING JAUNDICE UPPER ABDOMEN PAIN 
BT AT 
 
AT BT AT BT AT BT AT BT AT 
1 C80708 29 M + _ + _ + _ - _ _ _ + _ 
2 C84096 44 F + + + + _ _ _ _ _ _ + _ 
3 C84788 32 M + + + + + _ + _ + + + + 
4 C87981 44 M + _ + _ + + _ _ + + + _ 
5 C75157 46 M + _ + _ + _ _ _ + _ + _ 
6 C88089 25 M + + + _ + _ + _ + _ + _ 
7 5005 55 M + + + + + + _ _ + + + + 
8 C87693 26 M _ _ _ _ + _ _ _ + _ + _ 
9 c88638 35 M + _ + _ + + + _ + + + + 
10 c91112 60 M _ _ + _ + + _ _ + + + + 
11 C91323 60 F + _ _ _ + _ + _ _ _ + _ 
12 C90680 29 M + + + _ + _ + _ _ _ + _ 
13 C91558 60 M + _ + _ + _ _ _ _ - + _ 
14 C92972 43 M _ - + - + - + - + _ + _ 
15 C92771 26 M + + + _ + _ + _ _ _ + _ 
16 5087 34 M - _ + + + _ + _ + + + + 
17 C94608 30 M + _ + + + _ _ _ + _ + _ 
18 C13733 30 M + _ + _ _ _ + _ _ _ + _ 
19 DOO9130 49 M + _ _ _ + _ + _ + _ + _ 
20 D008583 39 M + _ + _ + + + _ + _ + _ 
SPECIFIC   INVESTIGATION FOR KALLRRAL NOI 
 
 
 
 
 
 
 
 
 
 
S.N
O 
OP/IP 
AG
E 
SE
X 
BTFB
S 
ATFB
S 
BTPB
S 
ATPB
S 
BTT
B 
ATT
B 
BTD
B 
ATD
B 
BTI
B 
ATI
B 
BTO
T 
ATO
T 
BTP
T 
ATP
T 
BTAL
P 
ATAL
P 
BTT
P 
ATT
P 
BTAL
B 
ATAL
B 
BTGL
O 
ATGL
O 
BTUB
S 
ATUB
S 
BTUB
P 
ATUB
P 
1 C80708 29 M 100 90 140 110 0.6 0.6 0.2 0.2 0.4 0.4 55 42 49 58 260 270 4.9 6.8 3.5 4.1 2.1 2.8 _ _ _ _ 
2 C84096 44 F 101 89 141 111 0.4 0.3 0.2 0.3 0.2 0.1 40 13 41 15 177 150 6.7 7.1 3.3 2.1 2.4 5 _ _ _ _ 
3 C84788 32 M 100 89 140 111 2.9 1.3 2.3 0.8 0.6 0.1 22 34 23 33 189 232 7.1 6.5 5.1 3.6 2 2.9 + _ + _ 
4 C87981 44 M 96 90 116 106 1.6 0.4 1.2 0.2 0.4 0.4 21 21 22 24 166 214 6.9 6.2 4.9 3.6 2 2.6 _ _ _ _ 
5 C75157 46 M 110 100 140 129 2 1.5 0.7 0.5 1.3 1 22 20 25 21 186 194 7 7 5 4 2 3 _ _ _ _ 
6 C88089 25 M 82 80 100 90 1.5 0.7 0.7 0.5 0.8 0.2 10 5 11 10 145 140 7.3 7.1 5.2 5 2.1 2.1 _ _ _ _ 
7 5005 55 M 85 90 147 110 5.1 3 2 1 3.1 2 17 10 18 15 168 150 7.4 7.4 4.6 4.6 2.8 2.8 + + + + 
8 C87693 26 M 74 104 90 121 3.5 1.9 1.1 0.6 2.4 1.3 78 16 100 17 240 140 7.8 5.9 4.9 3 2.9 2.9 _ _ - _ 
9 c88638 35 M 101 117 117 140 1.5 2 1.2 1.8 0.3 0.2 28 35 32 40 185 200 6.9 6.5 4.8 4.5 2.1 2 + _ + + 
10 c91112 60 M 90 115 134 200 1.7 2 1.3 1.1 0.4 0.9 24 30 26 40 220 133 6.9 7.2 4 4.8 2.9 2.4 + + + + 
11 C91323 60 F 110 94 130 104 0.5 0.7 0.2 0.3 3 0.4 45 40 46 36 149 155 6.9 7 4.2 4 2.3 3 _ _ _ _ 
12 C90680 29 M 94 90 120 110 0.5 0.7 0.2 0.5 0.3 0.2 127 46 124 60 290 180 7.4 7 5.1 5 2.3 2 _ _ _ _ 
13 C91558 60 M 120 104 159 149 0.5 0.7 0.2 0.3 0.3 0.4 40 22 43 24 199 171 5.5 6.5 3.2 3.6 2.3 2.9 _ _ _ _ 
14 C92972 43 M 98 96 114 118 1.9 1.2 0.8 0.5 1.1 0.7 22 27 27 32 87 130 6.7 6.4 3.8 4 2.9 2 _ _ _ _ 
15 C92771 26 M 80 90 110 120 0.3 0.4 0.1 0.2 0.2 0.2 32 20 33 21 184 200 5.1 7.5 3.1 4.7 2 2.8 _ _ _ _ 
16 5087 34 M 90 83 120 110 2.9 1.9 0.9 0.9 2 1 40 30 50 43 180 200 6.6 7 4.5 4.5 2.1 2.5 _ _ _ _ 
17 C94608 30 M 82 103 125 145 1.9 1.2 0.5 0.5 1.4 0.7 14 20 16 21 155 216 6.4 6.5 4 4.2 2.4 2.3 _ _ _ _ 
18 C13733 30 M 90 103 140 121 0.5 0.4 0.2 0.2 0.3 0.2 36 26 64 38 260 297 6.6 5.7 4.1 3 2.5 2.7 _ _ _ _ 
19 
DOO91
30 
49 M 104 100 118 110 2.9 0.7 1.2 0.3 1.7 0.4 156 40 82 30 207 41 5.9 5.2 3.7 3.2 2.2 2 _ _ + _ 
20 
D00858
3 
39 M 93 90 153 140 8 3.3 4.4 1.9 3.6 1.4 147 65 44 50 231 200 5.8 5.1 3.2 3.2 2.6 2.5 + + + + 
 
AFTER TREATMENT INVESTIGATION OF KALLERAL NOI 
 
 
 
 
 
S.N
O 
OP/IP NO 
A
G
E 
SE
X 
ATHB ATTC 
ATDC
P 
AT
DCL 
ATDC
E 
ATDC
M 
ATHE
SR 
ATOE
SR 
ATPL
T 
ATUR
EA 
ATCR
E 
ATCH
O 
ATHD
L 
ATLD
L 
ATVL
DL 
AUAL
B 
AU
FS 
AU
PS 
ATBS ATBP 
urobi
linog
en 
PUSCE
LLS 
EPI.C
ELLS 
1 C80708 29 M 15.8 9100 70 23 7 0 2 10 1.8 15 0.4 128 24 88 37 NIL NIL NIL NIL NEG NML 1-2P 1-2E 
2 C84096 44 F 12.6 8000 65 30 5 0 10 20 2.4 14 4 146 30 92 98 NIL NIL NIL NIL NEG NML 1-2P 1-2E 
3 C84788 32 M 17.3 8300 50 47 3 0 2 4 14 0.4 157 32 79 56 280 NIL NIL NIL NIL NEG NML 1-2P 1-2E 
4 C87981 44 M 16.6 7500 60 37 3 0 2 4 2.2 14 0.4 121 28 100 31 NIL NIL NIL NIL NEG NML 1-2P 1-2E 
5 C75157 46 M 15.4 5600 49 46 5 0 2 8 2.1 22 0.8 192 32 100 25 NIL NIL NIL NIL NEG NML 1-2P 1-2E 
6 C88089 25 M 16.5 10000 70 30 0 0 2 4 2.5 14 0.5 200 40 100 25 NIL NIL NIL NIL NEG NML 1-2P 1-2E 
7 5005 55 M 11 6000 70 25 5 0 22 40 1.2 16 0.3 97 40 90 14 NIL NIL NIL present POSITIVE NML 2-4P 2-4E 
8 5016 26 M 14.9 7400 65 30 5 0 2 4 2.6 14 0.4 144 38 94 35 NIL NIL NIL NIL NEG NML 1-2P 1-2E 
9 c88638 35 M 15 6900 70 28 2 0 2 8 2.2 20 0.6 200 38 100 40 NIL NIL NIL NIL NEG NML 1-2P 1-2E 
10 c91112 60 M 14.2 10300 70 24 6 0 4 16 3.1 30 0.9 247 49 131 44 NIL NIL NIL NIL NEG NML 1-2P 1-2E 
11 C91323 60 F 13.7 7700 65 30 5 0 4 8 2.4 14 0.4 205 42 98 39 NIL NIL NIL NIL NEG NML 1-2P 1-2E 
12 C90680 29 M 16.5 1000 70 30 0 0 2 4 2.5 14 0.5 200 40 100 25 NIL NIL NIL NIL NEG NML 1-2P 1-2E 
13 C91558 60 M 15.6 5300 66 29 5 0 2 4 2.5 22 0.7 159 42 80 66 NIL NIL NIL NIL NEG NML 1-2P 1-2E 
14 C92972 43 M 14.9 7000 55 39 5 0 2 6 2.6 17 0.6 196 36 26 133 NIL NIL NIL NIL NEG NML 1-2P 1-2E 
15 C92771 26 M 15.2 5600 61 30 9 0 2 6 2.9 14 0.4 160 32 80 15 NIL NIL NIL NIL NEG NML 1-2P 1-2E 
16 5087 34 M 17.8 5600 60 30 10 0 4 6 2.2 16 2.2 280 50 140 50 NIL NIL NIL NIL NEG NML 1-2P 1-2E 
17 C94608 30 M 12.2 6200 55 41 4 0 2 4 2.3 16 0.5 177 36 92 30 NIL NIL NIL NIL NEG NML 1-2P 1-2E 
18 C13733 30 M 12.9 8700 60 36 4 0 2 4 2.5 18 0.6 214 40 101 21 NIL NIL NIL NIL NEG NML 1-2P 1-2E 
19 DOO9130 49 M 13.3 7000 71 22 7 0 2 6 1.9 22 0.8 175 35 88 19 NIL NIL NIL NIL NEG NML 1-2P 1-2E 
20 D008583 39 M 11.6 9500 70 25 5 0 10 20 2 16 0.6 145 40 100 85 NIL NIL NIL NIL NEG NML 1-2P 1-2E 
  
 
BEFORE TREAT MENT  INVESTIGATIONS OF  KALLERAL NOI. 
 
S.NO 
 
 
OP/IP AGE SEX 
HB 
mg/dl 
TC 
Cells/cu.
mm 
DC % ESR mm 
PLT 
Cells/c
u.mm 
UREA 
mg/dl 
CRE 
mg/dl 
CHO 
mg/d
l 
HDL 
mg/dl 
LDL 
mg/dl 
VLD
L 
mg/
dl 
HBsAg UALB UFS UPS BS BP 
PUSCE
LLS 
Epi 
P L E M 
1\2HR 
 
1hr 
1 C80708 29 M 15 11300 67 28 5 0 16 32 2 14 0.4 147 32 94 18 NEG NIL NIL NIL NIL NEG 1-2P 1-2 E 
2 C84096 44 F 13 9100 70 27 30 0 8 18 2.9 22 0.6 194 26 145 287 NEG NIL NIL NIL NIL NEG 1-2P 1-2 E 
3 C84788 32 M 16 8600 40 52 8 0 2 10 3.3 20 0.7 177 34 106 42 NEG NIL NIL NIL NIL NEG 1-2P 1-2E 
4 C87981 44 M 17 7800 64 31 5 0 8 16 2 19 0.6 146 28 50 18 NEG NIL NIL NIL NIL NEG 1-2P 1-2 E 
5 C75157 46 M 16 5900 54 41 5 0 2 6 2.2 28 14 134 33 64 17 NEG NIL NIL NIL NIL NEG 1-2P 1-2E 
6 C88089 25 M 17 9600 70 25 5 0 2 6 2.9 14 0.4 275 45 218 59 NEG NIL NIL NIL NIL NEG 1-2P 1-2E 
7 5005 55 M 9.8 4000 62 30 8 0 44 88 0.8 16 0.5 97 20 108 22 NEG NIL NIL NIL PoS pre 2-4P 2-4E 
8 5016 26 M 14 6100 50 38 12 0 2 6 2.2 33 1 193 30 130 34 NEG NIL NIL NIL NIL NEG 1-2P 1-2E 
9 c88638 35 M 14 6600 54 42 4 0 8 18 3.2 14 0.1 227 35 195 44 NEG NIL NIL NIL NIL NEG 1-2P 1-2E 
10 c91112 60 M 14 8000 62 34 4 0 22 4 32 24 0.9 184 39 96 50 NEG NIL NIL NIL NIL NEG 1-2P 1-2E 
11 C91323 60 F 13 7300 65 30 5 0 6 16 2.5 16 0.5 217 35 139 46 NEG NIL NIL NIL NIL NEG 1-2P 1-2E 
12 C90680 29 M 17 9600 70 25 5 0 2 6 2.9 14 0.4 275 45 218 59 NEG NIL NIL NIL NIL NEG 1-2P 1-2E 
13 C91558 60 M 15 5900 64 29 6 1 6 14 2.6 18 0.5 172 42 123 98 NEG NIL NIL NIL NIL NEG 1-2P 1-2E 
14 C92972 43 M 18 8600 64 30 6 0 12 28 2.6 15 0.5 179 35 116 35 NEG NIL NIL NIL NIL NEG 1-2P 1-2E 
15 C92771 26 M 15 4700 62 36 2 0 2 4 2.7 20 0.6 159 32 119 17 NEG NIL NIL NIL NIL NEG 1-2P 2-3E 
16 5087 34 M 23 12600 86 12 2 0 2 4 1.1 20 0.7 360 30 17 17 NEG NIL NIL NIL NIL NEG 1-2P 1-2E 
17 C94608 30 M 15 7300 60 35 5 0 2 4 2.2 15 0.4 182 40 104 32 NEG NIL NIL NIL NIL NEG 1-2P 1-2E 
18 C13733 30 M 13 8500 60 35 5 0 6 12 5.1 18 0.6 183 36 64 49 NEG NIL NIL NIL NIL NEG 1-2P 1-2E 
19 DOO9130 49 M 16 11200 84 12 4 0 4 1 1.1 14 0.5 308 49 139 22 NEG NIL NIL NIL NIL NEG 1-2P 1-2E 
20 D008583 39 M 11 11000 70 24 6 0 14 30 2.4 14 0.4 248 45 112 28 NEG NIL NIL NIL Pos PRE 2-4P 1-2E 
 
PROGNOSIS BEFORE AND AFTER TREATMENT 
  
 
 
 
 
 
 
 
  
  
S.NO OP/IP 
 
USG    SCAN 
 
BT AT 
1 C80708 Fatty liver Normal study 
2 C84096 Fatty liver Normal study 
3 C84788 Fatty liver Normal study 
4 C87981 Fatty liver Fatty liver 
5 C75157 Fatty liver Normal Study 
6 C88089 Normal study Normal study 
7 5005 Fatty liver Fatty liver 
8 C87693 Normal   study Normal study 
9 c88638 Normal study Normal study 
10 c91112 Fatty liver Fatty liver 
11 C91323 Fatty liver Fatty liver 
12 C90680 Normal study Normal study 
13 C91558 Normal study Normal study 
14 C92972 Normal study Normal study 
15 C92771 Normal study Normal study 
16 5087 Normal study Normal study 
17 C94608 Fatty liver N ormal study 
18 C13733 Normal study Normal study 
19 DOO9130 Normal study Normal study 
20 D008583 Fatty liver Normal study 
  
 ABDOMEN & KUB SCAN REPORT 
Liver  : Liver shows  diffuse abnormal increased echoreflectivity . Focal fat sparing 
noted in the right lobe no abscess or mass lesion seen. CBD AND IHBR appear normal Liver 
measurement  -14.6cms. 
Gall bladder : Gall Bladder appeared normal. No calculus seen in gall bladder. CBD  
Appeared normal. No calculus seen in CBD. 
Pancreas : Pancreas appeared normal. 
Spleen  : Spleen appeared normal. Spleen measured 10.5 cms 
Aorta  : Aorta appeared normal. No Para aortic nodes seen. 
Peritoneal cavity: Peritoneal cavity appeared normal. 
Adrenals : Adrenals appeared normal. 
KUB 
RK  : Right Kidney measured 10.1 cms. Cortex and collecting system of right 
kidney  
Appeared normal. No calculi seen.   
LK  : Left Kidney measured 9.8 cms. Cortex and collecting system of left kidney  
Appeared normal. No calculi seen.   
BLADDER : Bladder appeared normal. 
PROSTATE : Prostrate appeared normal. Measured in 3.2 X 2.8 X 2.2 cms (Weight = 15.1  
GMS).No intra vesicle enlargement of prostate gland seen. 
 
IMPRESSION  
  Fatty liver  .No other abnormalities seen     
        
 
 
Patient Name: Mr. MURTHY Age/Sex: 47/M 
Referred by: Dr.Prabhapathy Visit Date:  19/07/2012 
  
 
 ABDOMEN & KUB SCAN REPORT 
Liver  : Liver shows  normal. Focal fat sparing noted in the right lobe no abscess or 
mass lesion seen. CBD AND IHBR appear normal. Liver measurement-12.6cms 
Gall bladder : Gall Bladder appeared normal. No calculus seen in gall bladder. CBD  
Appeared normal. No calculus seen in CBD. 
Pancreas : Pancreas appeared normal. 
Spleen  : Spleen appeared normal. Spleen measured 10.5 cms 
Aorta  : Aorta appeared normal. No Para aortic nodes seen. 
Peritoneal cavity: Peritoneal cavity appeared normal. 
Adrenals : Adrenals appeared normal. 
 
KUB 
RK  : Right Kidney measured 10.1 cms. Cortex and collecting system of right 
kidney  
Appeared normal. No calculi seen.   
LK  : Left Kidney measured 9.8 cms. Cortex and collecting system of left kidney  
Appeared normal. No calculi seen.   
BLADDER : Bladder appeared normal. 
PROSTATE : Prostrate appeared normal. Measured in 3.2 X 2.8 X 2.2 cms (Weight = 15.1  
GMS).No intra vesicle enlargement of prostate gland seen. 
 
IMPRESSION 
     Normal  study  :No other abnormalities seen    
            
        
Patient Name: Mr. MURTHY Age/Sex: 47/M 
Referred by: Dr.Prabhapathy Visit Date:  1/09/2012 
            
 
 
ABDOMEN & KUB SCAN REPORT 
Liver  : Liver shows normal with duffuse increase in echotexture . No 
abscess or mass lesion seen. Liver measured – 12.9cms 
Gall Bladder : Gall Bladder appeared normal. No calculus seen in Gall  
Bladder. CBD appeared normal. No calculus seen in CBD. 
Pancreas : Pancreas appeared normal. 
Spleen : Spleen appeared normal. Spleen measured 9.8cms 
Aorta  : Aorta appeared normal. No Para aortic nodes seen. 
Peritoneal cavity: Peritoneal cavity appeared normal. 
Adrenals : Adrenals appeared normal. 
 
KUB 
RK  : Right Kidney measured 9.5 X 3.9 cms. Cortex and collecting  
System of right kidney appeared normal. No calculi seen. 
LK  : Left Kidney measured 9.7 X 4.1 cms. Cortex and collecting  
System of left kidney appeared normal. No calculi seen.  
BLADDER : Bladder appeared normal. 
PROSTATE : Prostrate appeared normal. Measured in 2.8 X 2.5 X 1.9 cms  
(Weight = 14.4 gms). No intra vesicle enlargement of prostate 
gland seen. 
 
IMPRESSION 
FATTTY  LIVER .  
 
 
Patient Name: Mr. Nanthagopal Age/Sex: 29/M 
Referred by: Dr.Prabhapathy Visit Date: 22/7/2012 
 ABDOMEN & KUB SCAN REPORT 
ABDOMEN & KUB SCAN REPORT 
 
ABDOMEN & KUB SCAN REPORT 
 
Liver  : Liver shows normal. No abscess or mass lesion seen. Liver 
measured – 12.0cms 
Gall Bladder : Gall Bladder appeared normal. No calculus seen in Gall  
Bladder. CBD appeared normal. No calculus seen in CBD. 
Pancreas : Pancreas appeared normal. 
Spleen : Spleen appeared normal. Spleen measured 9.8cms 
Aorta  : Aorta appeared normal. No Para aortic nodes seen. 
Peritoneal cavity: Peritoneal cavity appeared normal. 
Adrenals : Adrenals appeared normal. 
 
KUB 
RK  : Right Kidney measured 9.5 X 3.9 cms. Cortex and collecting  
System of right kidney appeared normal. No calculi seen. 
LK  : Left Kidney measured 9.7 X 4.1 cms. Cortex and collecting  
System of left kidney appeared normal. No calculi seen.  
BLADDER : Bladder appeared normal. 
PROSTATE : Prostrate appeared normal. Measured in 2.8 X 2.5 X 1.9 cms  
(Weight = 14.4 gms). No intra vesicle enlargement of prostate 
gland seen. 
 
IMPRESSION 
Normal study. 
 
 
 
 
Patient Name: Mr. Nanthagopal Age/Sex: 29/M 
Referred by: Dr.Prabhapathy Visit Date: 4/10/2012 
            ABDOMEN & KUB SCAN REPORT 
 
 
Liver  : Liver  is mildly enlarged in size and measures 13.8 cms 
shows diffuse homogenus  increased echo texture.  
Gall Bladder: Gall Bladder appeared normal. No calculus seen in Gall  
Bladder. CBD appeared normal. No calculus seen in CBD. 
Pancreas : Pancreas appeared normal. 
Spleen : Spleen appeared normal. Spleen measured 9.8cms 
Aorta  : Aorta appeared normal. No Para aortic nodes seen. 
Peritoneal cavity: Peritoneal cavity appeared normal. 
Adrenals : Adrenals appeared normal. 
KUB 
RK  : Right Kidney measured 9.5 X 3.9 cms. Cortex and 
collecting System of right kidney appeared normal. No calculi  seen. 
 LK  : Left Kidney measured 9.7 X 4.1 cms. Cortex and 
collecting  
System of left kidney appeared normal. No calculi seen.
  
BLADDER : Bladder appeared normal. 
 
Patient Name: Mrs. Saraswathy Age/Sex: 44/f 
Referred by: Dr.Prabhapathy Visit Date: 4/7/2012 
 
 
UTERUS&OVARIES: 
  Not visualized consistent with post hysterectomy status. 
P.O.D: 
  P.O.D is free. 
  No adnexal mass lesion seen. 
 
Impression: 
 Mild hepatomegaly. 
 
 
 
 
 
 
 
 
                                                                                                          
 
 
      
 
 
 
 
 
            ABDOMEN & KUB SCAN REPORT 
 
 
Liver  : Liver shows normal. No abscess or mass lesion seen. Liver 
measured – 12.0cms.  
Gall Bladde : Gall Bladder appeared normal. No calculus seen in Gall  
Bladder. CBD appeared normal. No calculus seen in CBD. 
Pancreas : Pancreas appeared normal. 
Spleen : Spleen appeared normal. Spleen measured 9.8cms 
Aorta  : Aorta appeared normal. No Para aortic nodes seen. 
Peritoneal cavity: Peritoneal cavity appeared normal. 
Adrenals : Adrenals appeared normal. 
KUB 
RK  : Right Kidney measured 9.5 X 3.9 cms. Cortex and 
collecting System of right kidney appeared normal. No calculi  seen. 
 LK  : Left Kidney measured 9.7 X 4.1 cms. Cortex and 
collecting  
System of left kidney appeared normal. No calculi seen.
  
 
Patient Name: Mrs. Saraswathy Age/Sex: 44/f 
Referred by: Dr.Prabhapathy Visit Date: 10/9/2012 
 
 
BLADDER : Bladder appeared normal. 
 
UTERUS&OVARIES: 
  Not visualized consistent with post hysterectomy status. 
P.O.D: 
  P.O.D is free. 
  No adnexal mass lesion seen. 
 
Impression: 
 Normal study.  
 
 
 
       
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 ABDOMEN & KUB SCAN REPORT 
ABDOMEN & KUB SCAN REPORT 
 
ABDOMEN & KUB SCAN REPORT 
 
Liver  : Liver shows normal. No abscess or mass lesion seen. Liver 
measured – 12.0cms 
Gall Bladder : Gall Bladder appeared normal. No calculus seen in Gall  
Bladder. CBD appeared normal. No calculus seen in CBD. 
Pancreas : Pancreas appeared normal. 
Spleen : Spleen appeared normal. Spleen measured 9.8cms 
Aorta  : Aorta appeared normal. No Para aortic nodes seen. 
Peritoneal cavity: Peritoneal cavity appeared normal. 
Adrenals : Adrenals appeared normal. 
 
KUB 
RK  : Right Kidney measured 9.5 X 3.9 cms. Cortex and collecting  
System of right kidney appeared normal. No calculi seen. 
LK  : Left Kidney measured 9.7 X 4.1 cms. Cortex and collecting  
System of left kidney appeared normal. No calculi seen.  
BLADDER : Bladder appeared normal. 
PROSTATE : Prostrate appeared normal. Measured in 2.8 X 2.5 X 1.9 cms  
(Weight = 14.4 gms). No intra vesicle enlargement of prostate 
gland seen. 
 
IMPRESSION 
Normal study. 
 
 
 
 
Patient Name: Mr.Rajan Age/Sex: 39/M 
Referred by: Dr.Prabhapathy Visit Date: 4/1/2013 
Normal Study 
TABLES FOR TRAIL DRUG-2 CHITHIRAMOOLA RASAYANAM 
QUALITATIVE ANALYSIS: 
     Trail drug 2-Table 1 
.S.NO PARAMETERS RESULTS 
1. Phosphate  Present 
2. Sulphate Absent 
3. Magnesium Absent 
4. Iron Present 
5 Aminoacids Present 
6. Starch Absent 
7. Flavonoids Absent 
8. Proteins Absent 
9. Tannic acid Present 
10. Glycosides Absent 
 
 
PHYSICAL PROPERTIES 
Trail drug 2 table2 
 
S.NO 
 
                 Characteristic test 
 
     Results 
 
1. 
 
pH 
 
4.90 
 
2. 
 
Ash Value 
 
0.98 
 
3. 
 
Water soluble ash 
 
0.02 
 
           4. 
 
           Acid insoluble ash 
 
          0.01 
 
 
  
 
 
Preliminary acid, basic radicals screening of Chithiramoola Rasayanam. 
            
Trail drug 2 table3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.No. Constituents   CMR 
1. Calcium _ 
2. Iron (Ferric) + 
3. Iron (Ferrous) + 
4. Chloride _ 
5. Phosphate + 
6. Potassium _ 
7. Sodium + 
8. Sulphate _ 
108 – HPTLC Profile 
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Dose finding experiment and its behavioural Signs of Toxicity 
Trail drug 2 table4 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. 1000 + - - + - + - - - - - - - + - - - - - - 
2 2000 + - - + - + - - - - - - - + - - - - - - 
3 5000 + - - + - + - - - - - - - + - - + - -  - 
 
 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. Decreased Motor Activity 8. Tremors 9. 
Convulsions 10. Muscle Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. Exophthalmos 17. Diarrhoea 
18. Writhing 19. Respiration 20. Mortality 
 
Body wt (g) of albino rats exposed to Chithiramoola Rasayanam for 28days. 
Trail drug 2 table5 
Dose (mg/kg/day) Days 
1 7 14 21 28 
Control 164.06±1.80 165.51±1.10 167.60±2.5 168.75±2.7 168.75±2.2 
100 150.1±1.22* 151.6±1.82* 152.51±0.20** 154.50±0.2 155.3±0.3 
250 152.4±0.72 153.14±1.04* 155.00±1.32* 160.25±2.36 160.20±2.3 
500 145.08±7.4** 146.22±6.20** 153.55±4.91** 148.61±11.2 149.02±7.10** 
 
Values are mean ± S.E.M. (Dunnett's test). *P<0.05; **P<0.01. N=6. 
 
 
Food (g/day) intake of rats exposed to Chithiramoola Rasayanam for 28days. 
Trail drug 2 table6 
Dose (mg/kg/day) Days (gms/rats) 
1 7 14 21 28 
Control 41.18±2.54 40.12±2.15 42.17±2.16 45.11±2.14 42.18±2.17 
100 40.45±2.74 45.15±2.14 44.48±2.24 45.00±2.91 42.10±2.48 
250 40.24±2.47 42.33±2.10 42.84±2.45 44.26±2.20 43.24±2.15 
500 41.18±2.26 40.48±2.28 43.28±2.48 40.10±2.22 42.34±2.45 
 
Values are mean ± S.E.M. (Dunnet ’t' test). nsP>0.05 Vs Control N=6. 
 
 
Water (ml/day) intake of rats exposed to Chithiramoola Rasayanam for 28days. 
Trail drug 2 table7 
 
Dose (mg/kg/day) 
Days(ml/rat) 
1 7 14 21 28 
Control 45.34±2.31 42.33±2.74 44.16±4.15 45.20±3.35 42.92±3.00 
100 40.40±2.27 43.40±3.11 45.66±3.63 44.31±3.00 45.54±2.51 
250 42.48±2.72 42.12±2.54 43.12±3.16 42.52±2.64 47.40±3.20 
500 46.32±2.61 44.30±2.12 45.90±3.07 45.27±3.44 45.28±3.22 
 
Values are mean ± S.E.M. (Dunnet ’t' test). nsP>0.05 Vs Control N=6. 
 
 
Hematological parameters after 28days treatment with Chithiramoola Rasayanam in rats. 
Trail drug 2 table8 
Parameter Control 100 mg/kg 250 mg/kg 500 mg/kg 
Red blood cell (mm3) 4.45±0.41 4.90±0.43 4.72±0.32 4.28±0.18 
HB (%) 14.51±0.45 14.2±0.80 14.52±0.40 14.80±0.28 
Leukocyte (x103/Cu.mm) 3.15±0.4 3.18±0.5 2.60±0.30 2.72±0.37 
Platelets(K/µl) 1.12±0.12 1.42±0.25 1.42±0.25 1.52±0.22 
MCV (gl) 85.13±4.4 86.12±4.10 85.51±3.20 85.12±7.02 
N 50.10±4.50 45.10 ±2.7 47.22±2.8 47.20±3.2 
L 47.00±0.6 46.14±3.18 48.24±1.42 50.60±2.01 
M 4.0±0.02 3.4±0.2* 4.0±0.3 3.2±0.2* 
E 6.2±0.40 5±0.5 5±0.4 5±0.4 
B 0±0.00 0±0.00 0±0.00 0±0.00 
ESR(mm) 1±00 1±00 1±00 1±00 
PCV 44.12±2.0 43.21±2.30 42.10±2.44 42.20±3.02 
 
 
Effect of treatment with Chithiramoola Rasayanam biochemical parameters. 
Trail drug 2 table9 
Dose (mg/kg) Control 100 mg/kg 250 mg/kg 500 mg/kg 
Total Bilirubin (mg/dL) 0.23±0.01 0.24±0.03 0.25±0.03 1.41±1.07 
Bilirubin direct (mg/dL) 0.00±0.00 0.02±0.01 0.00±0.00 0.13±0.13 
ALP (U/L) 51.20±4.25 38.80±2.80 53.60±3.28 50.60±6.29 
SGOT (U/L) 125.2±6.70 130.10±5.29 137.90±7.16 215.10±62.70 
SGPT(U/L) 24.52±1.40 25.32±2.12 27.00±1.80 47.12±3.58** 
Total Protein(g/dl) 5.12±0.26 5.54±0.21 5.52±0.14 6.10±0.30* 
Albumin(g/dl) 3.90±0.06 3.71±0.05 3.62±0.07* 3.73±0.07 
Globulin(g/dl) 3.98±0.15 4.10±0.22 4.08±0.16 4.56±0.24 
 
Values are mean ± S.E.M. *P<0.05; **P<0.01. Vs Control N=6. 
 
Trail drug 2 table10 
Dose (mg/kg) Control 100 mg/kg 250 mg/kg 500 mg/kg 
Urea(µg/dL) 30.67±4.3 37.67±4.3 38.00±5.6 34.50±4.68 
Creatinine (mg/dL) 29.38±2.2 31.38±3.3 28.01±2.01 29.19 ± 5.2 
Uric acid (mg/dL) 3.30±0.05 1.98±0.07** 2.10±0.08** 1.37±0.08** 
Na m.mol 149.80±0.84 148.00±1.00 147.20±1.10 146.60±0.55 
K m.mol 6.12±0.58 5.90±1.00 5.68±0.08 5.82±0.08 
Cl m.mol 98.14±3.54 102.78±5.00 104.35±4.95 102.70±5.44 
 
Values are mean ± S.E.M. **P<0.01. Vs Control N=6. 
 
 
Lipid Profile 
Trail drug 2 table11 
Dose (mg/kg) Control 100 mg/kg 250 mg/kg 500 mg/kg 
Total cholesterol (mg/dL) 56.86±5.77 57.61±5.68 55.84±5.21 52.50±3.04 
HDL(mg/dL) 95.31±0.25 104.5±0.22** 163.67±0.27** 150.39±0.49** 
LDL(mg/dL) 81.44±2.50 32.48±4.75** 95.60±0.60* 71.77±3.50 
VLDL(mg/dl) 25.10±2.00 24.72±2.24 25.48±2.95 25.24±2.48 
Triglycerides (mg/dl) 25.3±4.2 27.33±5.2 28.94±4 30.75±4.2 
Blood glucose(mg/dl) 102±13.4 90±10.6 105±18.7 113±15.52 
 
Values are mean ± S.E.M. *P<0.05; **P<0.01. Vs Control N=6. 
 
Urine Analysis 
Trail drug 2 table12 
Parameters Control 100 mg/kg 250 mg/kg 500 mg/kg 
Colour Yellow Yellow Yellow Yellow 
Transparency Clear Slightly turbid Slightly cloudy Slightly turbid 
Specific gravity 1.010 1.010 1.010 1.010 
PH >7.2 >8.0 >7.5 >7.5 
Protein Nil 1+ 1+ 2+ 
Glucose Nil Nil Nil Trace 
Bilirubin -ve -ve -ve -ve 
Ketones -ve -ve -ve -ve 
Blood Absent Absent Absent Absent 
Urobilinogen Normal Normal Normal Normal 
Pus cells 0-cells/HPF 1-cell/HPF 2-cells/HPF 1-cell/HPF 
RBCs Nil Nil 0-1cells/HPF Nil 
Epithelial cells Nil 1-cell/HPF Nil 1-cell/HPF 
Crystals Nil Nil Nil Nil 
Casts Nil Nil Nil Nil 
Others Bacteria seen Bacteria seen Bacteria seen Bacteria seen 
 
Effect of oral administration of Chithiramoola Rasayanam on organ weight 
Trail drug 2 table13 
Dose (mg/kg) Control 100 mg/kg 250 mg/kg 500 mg/kg 
Liver (g) 6.50±0.44 6.72±0.38 6.44±0.32 6.35±0.30 
Heart (g) 1.24±0.05 1.31±0.05 1.17±0.04 1.25±0.05 
Lung (g) 1.88±0.13 1.72±0.05 1.78±0.12 1.68±0.06 
Spleen (g) 0.90±0.04 0.85±0.03 0.77±0.03* 0.81±0.04 
Ovary (g) 0.07±0.00 0.08±0.00 0.09±0.00 0.06±0.03 
Testes (g) 2.00±0.10 2.15±0.15 2.24±0.20 2.05±0.18 
Brain (g) 1.90±0.02 1.91±0.03 1.80±0.03* 1.92±0.03 
Kidney (g) 1.26±0.03 1.25±0.03 1.14±0.02* 1.25±0.03 
Stomach (g) 1.25±0.18 1.20±0.12 1.14±0.14 1.18±0.15 
Values are mean ± S.E.M. (Dunnet ’t' test). *P<0.05; Vs Control N=6. 
 
Analgesic activity of Chitramoola Rasayanam in mice 
Trail drug 2 table14 
 
Drug and 
Route 
 
Dose 
(mg/kg) 
 
No. of 
animals 
 
Reaction 
time before 
treatment 
% increase in Reaction time in Sec after CMR treatment  
(Mean ± SEM) 
15min** 30min** 45min** 60min** 90min** 
Control saline 6 3.0±0.05 5.2±0.8 12.4±0.5 12.1±0.04 13.5±0.6 14.16±0.4 
CMR 100 6 3.1±0.04 8.2±0.12 13.8±0.10 24.5±0.44 31.18±1.20 34.12±2.18 
CMR 250 6 2.9±0.05 10.1±0.12 20.1±0.14 35.6±0.52 46.20±1.15 49.00±2.32 
CMR 500 6 3.0±0.08 11.6±0.10 31.4±0.12 41.2±0.5 48.89±1.24 52.10±2.00 
Pentazocine 5 6 3.3±0.14 31.10±0.24 52.1±0.32 70.02±1.03 69.38±2.70 68.13±1.77 
 
Values are expressed as mean±SEM; ** P<0.01, as compared to their control 
 
 
CLINICAL  ASSESMENT: 
    AGE DISTRIBUTION 
  
AGE YRS NO  OF  PATIENT % 
30-40 5 25 
40-50 5 25 
50-60 9 45 
60-70 1 5 
 
 
 
 
 
GENDER  DISTRIBUTION 
 
S.NO GENDER 
NO.OF 
PATIENTS 
PERCENTAGE 
1. FEMALE 5 25% 
2. MALE 15 75% 
 
 
 
 
 
0%
20%
40%
60%
30-40yrs
40-50yrs
50-60yrs
60-70yrs
25% 25%
45%
5%
Age distribution
25%
75%
Gender distribution
male
female
IMPROVEMENT IN THE PAIN SCORE OF THE  SOOLAI  PATIENTS 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO OPD NO/ IP NO. AGE BT AT 
1 4934 58 7 4 
2 C83793 40 6 2 
3 C24806 62 4 1 
4 C85159 39 6 2 
5 C87411 49 5 2 
6 4972 39 7 3 
7 4018 43 3 1 
8 4989 34 6 0 
9 C87560 50 3 0 
10 C84893 50 4 1 
11 C89473 56 5 2 
12 4060 56 6 1 
13 C90735 50 4 2 
14 4124 49 5 2 
15 C89474 52 7 3 
16 5068 55 6 2 
17 C86851 52 4 0 
18 C86535 36 5 2 
19 C94410 35 4 1 
20 C95642 44 4 2 
IMPROVEMENT  SHOWING SIGNS AND SYMPTOMS BEFORE AND AFTER 
TREATMENT OF SOOLAI . 
 
 
 
 
 
BT-BEFORE TREATMENT 
AT- AFTER TREATMENT 
AT - AFTER TREATMENT NO IMPROVEMENT 
SYMPTOMS        NO. OF PATIENTS  WITH SYMPTOMS 
   BT       AFTER   TREATMENT IMPROVEM
ENT 
PERCENTA
GE 
NO 
IMPROVEM
ENT 
IMPROVE
MENT 
PAIN 20 (100%) 1(5%) 19 (95%) 95% 
SWELLING 18(90%) 2(11%) 16 (89%) 89% 
STIFFNESS 17(85%) 5(29%) 12 (71%) 71% 
CREPITUS 18(90%) 9(50%) 9  (50%) 50% 
RESTRICTED 
MOVEMENTS 
20(100%) 3(15%) 17 (85%) 85% 
100%
90% 85% 90%
100%
5% 11%
29%
50%
15%
95% 89%
71%
50%
85%
0%
20%
40%
60%
80%
100%
120%
pain swelling stiffness crepitusrestricted movements
BT
AT N0 I
AT I
    IMPROVEMENT IN  PROGNOSIS OF SYMPTOMS OF SOOLAI. 
 
 
 
 
BT-BEFORE TREATMENT,KP-KNEE PAIN, KS-KNEE SWELLING ,STIFF- STIFFNESS,CRE-CREPITUS,RES-RESTRICTION, SYM-SYMPTOMS. 
AT-AFTER  TREATMEN 
S.N0 op/ip AGE SEX BTKP ATKP BTKS ATKS BTSTIFF ATSTIFF BTCRE ATCRE BTRES ATRES BTSYM ATSYM 
1 4934 58 M + _ _ _ + _ + + + _ 4 1 
2 C83793 40 F + _ + _ + _ + _ + _ 5 0 
3 3983 62 F + _ + _ + + + + + + 5 4 
4 C85159 39 F + _ + _ _ _ + + + _ 4 1 
5 C87411 49 F + + + _ + _ + + + + 5 3 
6 4972 39 M + _ + _ _ _ + _ + _ 3 0 
7 4018 43 F + _ + _ + _ + + + _ 5 1 
8 4989 34 M + _ + _ _ _ + _ + _ 4 0 
9 C87560 50 F + _ + _ + _ + + + _ 5 1 
10 C84893 50 M + _ + _ + + + + + _ 5 1 
11 C89473 56 F + _ _ _ + _ + + + _ 4 1 
12 4060 56 F + _ _ _ + _ + + + _ 4 1 
13 C90735 50 F + _ + _ + _ + _ + _ 5 0 
14 4124 49 F + _ + _ + _ + + + + 5 3 
15 C89474 52 F + _ + _ + + + + + _ 5 2 
16 5068 55 M + _ + _ + _ + _ + _ 5 0 
17 C86851 52 F + _ + _ + _ + + + _ 5 1 
18 C86535 36 F + _ + _ + _ _ + + _ 5 1 
19 C94410 27 F + _ + _ + + + _ + _ 5 1 
20 C95642 44 F + _ + _ + + _ _ + _ 5 1 
SPECIFIC   INVESTIGATION FOR SOOLAI 
 
  
S.NO OP/IP AGE SEX BTHB 
Mg/dl 
ATHB 
Mg/dl  
BTHESR 
MM 
ATHESR 
MM 
BTOESR  
MM  
ATOESR 
MM 
BTDCP 
% 
ATDCP 
% 
BTDCL 
% 
ATDCL 
% 
BTSCAL 
Mg/dl 
ATSCAI 
Mg/dl 
1 4934 58 M 12 12.2 4 2 8 4 58 54 25 39 12 11.6 
2 C83793 40 F 12 12.7 30 4 64 20 63 64 34 30 10 9.8 
3 C24806 62 F 13 12.8 42 6 86 20 86 20 36 35 10 10.9 
4 C85159 39 F 14 13.1 2 4 8 16 30 69 68 26 11 10 
5 C87411 49 F 13 12.6 4 8 20 40 55 65 40 30 11 9.8 
6 4972 39 M 15 14.9 2 2 4 10 64 65 33 31 11 11 
7 4018 43 F 14 13.8 4 4 8 16 50 50 46 47 10 10 
8 4989 34 M 18 15.6 2 2 4 4 54 50 40 37 11 10.7 
9 C87560 50 F 12 11.9 2 2 4 6 60 62 31 33 10 10.6 
10 C84893 50 M 15 14.9 2 2 4 4 68 60 28 30 12 10.2 
11 C89473 56 F 13 12.7 6 4 20 14 53 50 41 40 11 10.5 
12 4060 56 F 13 13.6 8 4 16 5 61 50 36 45 11 10 
13 C90735 50 F 13 13 4 2 10 6 65 60 34 29 11 11.2 
14 4124 49 F 14 11.9 8 4 20 12 59 50 35 46 11 10 
15 C89474 52 F 13 12.3 10 2 22 6 72 67 26 29 12 10.6 
16 5068 55 M 14 10.9 2 2 4 8 65 62 35 28 11 10.6 
17 C86851 52 F 13 11.9 8 2 16 8 59 62 35 34 11 10 
18 C86535 36 F 13 11 4 2 8 4 60 60 35 36 9.9 10.8 
19 C94410 27 F 12 10.8 2 2 8 10 56 55 39 40 10 10.5 
20 C95642 44 F 14 11.4 10 6 24 12 65 67 34 30 11 10.3 
 
Drug2 BEFORE TREATMENT INVESTIGATION 
 
 
 
 
S.N
O 
OP/IP AGE SEX HB 
Mg/dl 
TC 
Cells/cu.
mm 
                   DC 
  
FBS 
Mg/dl 
PPBS 
mg/dl 
URE
A 
mg/dl 
CRE
m 
mg/dl 
URI 
mg/dl 
CH
O 
mg/dl 
HDL 
mg/dl 
LDL 
mg/dl 
VLD
L 
mg/dl 
TB 
Mg/dl 
DB 
Mg/dl  
IB 
Mg/dl 
OT 
U/L 
PT 
U/L 
ALP 
Mg/
dl 
TP 
Mg/dl 
ALB 
Mg/dl 
GLO 
Mg/dl 
 
ASO CRP RAF 
 
UAL
B 
UFS UPS P.C E.P 
P L M N 
1 4934 58 M 12.2 7700 58 25 17 0 110 112 18 0.6 6.9 237 37 147 77 O.7 0.5 0.2 23 25 149 7 5 2 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
2 C83793 40 F 12.3 11300 63 34 3 0 95 134 17 0.5 6 190 30 121 40 0.7 0.2 0.5 11 12 162 6 4 2 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
3 C24806 62 F 13 6200 57 36 6 1 95 103 14 0.5 3.8 142 38 64 22 0.5 0.3 0.2 29 30 196 7.6 4.2 3.4 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
4 C85159 39 F 13.6 8700 30 68 2 0 89 124 23 0.6 4.5 138 24 78 29 0.7 0.3 0.4 20 21 182 6 4 2 NEG NEG NEG NIL NIL NIL I-
2P 
I-2E 
5 C87411 49 F 12.9 8000 55 40 5 0 110 160 14 0.4 5.8 232 40 50 67 0.6 0.2 0.4 22 24 164 7.4 4.2 3.2 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
6 4972 39 M 14.9 6700 64 33 3 0 91 134 16 0.5 4 173 32 93 58 0.5 0.2 0.3 21 24 217 6.7 4.7 2 NEG NEG NEG NIL NIL NIL 2-
4P 
2-4E 
7 4018 43 F 13.6 6300 50 46 4 0 84 108 28 0.7 5.6 180 30 100 40 0.7 0.3 0.2 26 27 170 7.4 4 3.7 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
8 4989 34 M 17.7 9200 54 40 6 0 95 105 22 0.6 7.3 151 32 62 31 0.5 0.2 0.3 25 26 179 6.6 4 2.6 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
9 C87560 50 F 11.6 9600 60 31 9 0 101 139 20 0.6 4.5 158 39 70 42 0.4 0.2 0.2 14 16 130 7 5 2 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
10 C84893 50 M 15.3 7700 68 28 4 0 109 132 24 0.6 4.8 191 35 132 18 0.6 0.2 0.4 18 19 130 7 4.2 2.8 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
11 C89473 56 F 13.1 9700 53 41 6 0 118 122 16 0.5 6.6 201 35 101 76 0.3 0.2 0.1 12 11 132 7.6 5.2 2.4 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
12 4060 56 F 13.4 7900 61 36 3 0 105 124 27 0.7 3.8 182 40 126 18 0.5 0.2 0.3 14 16 162 6.6 4.1 2.5 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
13 C90735 50 F 12.6 6400 65 34 1 0 99 118 16 0.5 4.1 170 36 123 19 0.6 0.2 0.4 20 21 150 6.6 4.2 2.4 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
14 4124 49 F 14.1 7200 59 35 6 0 89 119 22 0.6 4.5 210 40 126 45 0.4 0.2 0.2 12 14 154 7 4.6 2.4 NEG NEG NEG NIL NIL NIL 2-
4P 
2-4E 
15 C89474 52 F 12.5 10300 72 26 2 0 90 132 14 0.4 5.5 216 36 140 34 0.5 0.2 0.3 24 25 198 7.9 5.3 2.6 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
16 5068 55 M 13.1 7100 65 35 10 0 100 120 27 0.6 4 206 36 126 27 0.6 0.2 0.4 26 29 243 6 4 2 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
17 C86851 52 F 12.6 6300 59 35 5 0 112 133 20 0.7 3.3 193 40 26 18 0.5 0.2 0.3 13 15 152 6.2 4.2 2 NEG NEG NEG NIL NIL NIL 1-
2p 
1-2E 
18 C86535 36 F 12.7 9000 60 35 5 0 84 132 26 0.7 4.4 128 30 92 17 0.6 0.2 0.4 23 25 149 6.7 4.2 2.5 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
19 C94410 35 F 11.8 4800 56 39 5 0 103 115 15 0.4 5 135 30 101 20 0.5 0.2 0.3 14 16 172 6.4 4.1 2.3 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
20 C95642 44 F 13.6 7600 65 34 1 0 101 118 17 0.5 4 171 35 121 24 0.6 0.2 0.4 14 18 226 7.1 4.4 2.7 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
AFTER TREATMENT –SOOLAI 
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1 4934 58 M 12.3 7700 54 39 7 0 110 120 18 0.5 3.1 200 43 120 40 0.4 0.2 0.
2 
25 25 120 7 5 2 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
2 C83793 40 F 12.7 11600 64 30 6 0 94 104 17 0.5 3 205 40 125 45 0.7 0.3 0.
4 
12 15 164 6 4 2 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
3 C24806 62 F 12.8 6200 40 35 24 1 108 121 18 0.5 3.6 141 32 106 21 0.7 0.3 0.
4 
17 18 159 5.9 3.2 2.7 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
4 C85159 39 F 13.1 9000 69 26 5 0 79 103 15 0.4 3.2 115 30 60 23 0.5 0.2 0.
3 
19 21 150 5.7 3.7 2 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
5 C87411 49 F 12.3 9500 65 30 5 0 110 130 21 0.6 4.7 246 49 132 77 0.5 0.2 0.
3 
16 18 151 7 5 2 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
6 4972 39 M 14.9 8900 65 31 4 0 118 137 19 0.5 4 165 40 72 35 0.5 0.2 0.
3 
17 18 156 5.8 3.1 2.7 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
7 4018 43 F 13.8 6500 50 47 3 0 92 134 22 0.6 3.8 167 36 107 23 0.6 0.2 0.
4 
12 12 157 7 5 2 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
8 4989 34 M 15.6 9400 50 37 13 0 100 133 20 0.6 4.8 115 26 26 21 0.5 0.2 0.
3 
12 14 201 5 3 2 NEG NEG NEG NIL NIL NIL 2-
3P 
2-3E 
9 C87560 50 F 11.9 11900 62 33 5 0 105 120 20 0.6   1 140 35 86 28 0.5 0.2 0.
3 
16 17 189 5 3 2 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
10 C84893 50 M 14.9 7500 60 30 5 0 88 100 18 0.5 3 200 40 99 26 0.7 3 0.
4 
17 19 175 6.2 3.7 2.5 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
11 C89473 56 F 12.7 7800 50 40 10 0 100 110 15 0.4 4.3 200 40 48 98 0.4 0.2 0.
2 
14 15 159 5.1 3 2.1 NEG NEG NEG NIL NIL NIL 4-
5P 
4-5E 
12 4060 56 F 13.6 6700 50 45 5 0 91 102 15 0.6 3.3 177 36 80 28 0.7 0.3 0.
4 
17 19 159 6.5 3.6 2.9 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
13 C90735 50 F 13 5800 60 29 11 0 92 106 20 0.9 3.3 173 45 86 35 0.5 0.2 0.
3 
12 14 196 5.7 3.1 2.6 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
14 4124 49 F 11.9 6800 50 46 4 0 107 125 14 0.7 4.1 239 47 119 91 0.5 0.2 0.
3 
17 19 179 6.2 3.9 2.3 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
15 C89474 52 F 12.3 9800 67 29 4 0 117 124 26 0.7 3.4 200 42 132 46 0.4 0.2 0.
2 
16 18 120 6.3 3.7 2.6 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
16 5068 55 M 10.9 8200 62 28 10 0 102 137 20 0.7 3.9 200 34 101 13 0.5 0.2 0.
3 
24 26 216 6.9 3.8 3.1 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
17 C86851 52 F 11.9 5900 62 34 4 0 127 157 23 0.7 3.4 210 33 108 26 0.5 0.2 0.
3 
20 22 183 6.9 3.7 3.2 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
18 C86535 36 F 11 6100 60 36 4 0 95 107 15 0.5 3 131 31 69 10 0.6 0.2 0.
4 
11 12 152 5.2 3.1 2.1 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
19 C94410 35 F 11 4800 55 40 5 0 113 123 14 0.5 3 135 33 72 87 0.7 0.3 0.
4 
15 17 159 6.7 4.2 2.5 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
20 C95642 44 F 11.4 9500 67 30 3 0 94 104 16 0.6 170 33 78 12 64 0.6 0.2 0.
4 
12 13 181 3.7 2.3 1.4 NEG NEG NEG NIL NIL NIL 1-
2P 
1-2E 
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STATISTICAL ANALYSIS: 
All collected data were entered into MS Excel software using different columns as 
variables and rows as patients. SPSS software was used to perform statistical analysis. 
Basic descriptive statistics include frequency distributions and cross-tabulations were 
performed. The quantity variables were expressed as Mean ± Standard Deviation and 
qualitative data as percentage. A probability value of <0.05 was considered to indicate as 
statistical significance. Paired ‘t’ test was performed for determining the significance 
between before and after treatment. 
DRUG 2 
   SOOLAI 
Paired t test for Symptoms before and after treatment: 
Variable Obs Mean Std.dev t.value P value 
Before 
treatment 
20 
 
4.65 
 
0.587 
 
14.888 P<0.0005 
After 
treatment 
20 1.15 1.089 
 
 
Symptoms before treatment is 4.65 and after treatment is 1.089 which is 
statistically significant(p<0.0005). 
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